WO2018111989A1 - Fibroblast activation protein (fap)-targeted imaging and therapy - Google Patents
Fibroblast activation protein (fap)-targeted imaging and therapy Download PDFInfo
- Publication number
- WO2018111989A1 WO2018111989A1 PCT/US2017/065995 US2017065995W WO2018111989A1 WO 2018111989 A1 WO2018111989 A1 WO 2018111989A1 US 2017065995 W US2017065995 W US 2017065995W WO 2018111989 A1 WO2018111989 A1 WO 2018111989A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugate
- pharmaceutically acceptable
- acceptable salt
- alkyl
- alkynyl
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 19
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 18
- 230000004913 activation Effects 0.000 title claims abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 153
- 238000000034 method Methods 0.000 claims abstract description 68
- 201000011510 cancer Diseases 0.000 claims abstract description 67
- 239000003112 inhibitor Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 113
- 210000004027 cell Anatomy 0.000 claims description 106
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 65
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 65
- 239000000975 dye Substances 0.000 claims description 51
- -1 geldanomycin Chemical compound 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 46
- 150000002367 halogens Chemical class 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 37
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 33
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 30
- 229930184737 tubulysin Natural products 0.000 claims description 21
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 238000000338 in vitro Methods 0.000 claims description 19
- 230000002285 radioactive effect Effects 0.000 claims description 18
- 239000012216 imaging agent Substances 0.000 claims description 17
- 210000003734 kidney Anatomy 0.000 claims description 17
- 235000018102 proteins Nutrition 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 150000002825 nitriles Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 201000000849 skin cancer Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 230000002357 endometrial effect Effects 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 230000002611 ovarian Effects 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- SDOFMBGMRVAJNF-SLPGGIOYSA-N (2r,3r,4r,5s)-6-aminohexane-1,2,3,4,5-pentol Chemical group NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-SLPGGIOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- HWCIETDQUHYHGQ-YHVCZDCZSA-N Tubulysin B Chemical compound C([C@@H](C[C@H](C)C(O)=O)NC(=O)C=1N=C(SC=1)[C@H](OC(C)=O)C[C@@H](N(COC(=O)CCC)C(=O)[C@@H](NC(=O)[C@@H]1N(CCCC1)C)[C@@H](C)CC)C(C)C)C1=CC=C(O)C=C1 HWCIETDQUHYHGQ-YHVCZDCZSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 210000002536 stromal cell Anatomy 0.000 claims description 4
- HWCIETDQUHYHGQ-UHFFFAOYSA-N tubulysin B Natural products C1CCCN(C)C1C(=O)NC(C(C)CC)C(=O)N(COC(=O)CCC)C(C(C)C)CC(OC(C)=O)C(SC=1)=NC=1C(=O)NC(CC(C)C(O)=O)CC1=CC=C(O)C=C1 HWCIETDQUHYHGQ-UHFFFAOYSA-N 0.000 claims description 4
- 108010061146 tubulysin B Proteins 0.000 claims description 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 150000002307 glutamic acids Chemical class 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 150000002527 isonitriles Chemical class 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- NZCNGJHOIKMMCG-UZRVFEFTSA-N (2S,4R)-4-[[2-[(1R,3R)-1-acetyloxy-4-methyl-3-[[(2S,3S)-3-methyl-2-[[(2R)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]-(propanoyloxymethyl)amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-5-(4-hydroxyphenyl)-2-methylpentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C NZCNGJHOIKMMCG-UZRVFEFTSA-N 0.000 claims description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- 229930188224 Cryptophycin Natural products 0.000 claims description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
- 229930126263 Maytansine Natural products 0.000 claims description 2
- QJZRFPJCWMNVAV-HHHXNRCGSA-N N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methylbenzamide Chemical compound NCCCN([C@H](C(C)C)C=1N(C(=O)C2=CC=C(Cl)C=C2N=1)CC=1C=CC=CC=1)C(=O)C1=CC=C(C)C=C1 QJZRFPJCWMNVAV-HHHXNRCGSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- IBEDDHUHZBDXGB-UHFFFAOYSA-N Tubulysin A Natural products N=1C(C(=O)NC(CC(C)C(O)=O)CC=2C=CC(O)=CC=2)=CSC=1C(OC(C)=O)CC(C(C)C)N(COC(=O)CC(C)C)C(=O)C(C(C)CC)NC(=O)C1CCCCN1C IBEDDHUHZBDXGB-UHFFFAOYSA-N 0.000 claims description 2
- IBEDDHUHZBDXGB-OEJISELMSA-N Tubulysin A Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IBEDDHUHZBDXGB-OEJISELMSA-N 0.000 claims description 2
- SAJNCFZAPSBQTQ-HZZFHOQESA-N Tubulysin D Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C SAJNCFZAPSBQTQ-HZZFHOQESA-N 0.000 claims description 2
- SEIXESXDPXDGRK-CAPJTEJHSA-N Tubulysin E Chemical compound C([C@@H](C[C@H](C)C(O)=O)NC(=O)C=1N=C(SC=1)[C@H](OC(C)=O)C[C@@H](N(COC(=O)CCC)C(=O)[C@@H](NC(=O)[C@@H]1N(CCCC1)C)[C@@H](C)CC)C(C)C)C1=CC=CC=C1 SEIXESXDPXDGRK-CAPJTEJHSA-N 0.000 claims description 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 2
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 2
- 229960003896 aminopterin Drugs 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 108010006226 cryptophycin Proteins 0.000 claims description 2
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 claims description 2
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002448 dasatinib Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- KYHUYMLIVQFXRI-UHFFFAOYSA-N didemnin B Natural products CC1OC(=O)C(CC=2C=CC(OC)=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC(C)C)NC(=O)C(C)C(=O)C(C(C)C)OC(=O)CC(O)C(C(C)CC)NC(=O)C1NC(=O)C(CC(C)C)N(C)C(=O)C1CCCN1C(=O)C(C)O KYHUYMLIVQFXRI-UHFFFAOYSA-N 0.000 claims description 2
- 108010061297 didemnins Proteins 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229930013356 epothilone Natural products 0.000 claims description 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229950007344 ispinesib Drugs 0.000 claims description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- PMXCMJLOPOFPBT-HNNXBMFYSA-N purvalanol A Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PMXCMJLOPOFPBT-HNNXBMFYSA-N 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 108010061145 tubulysin A Proteins 0.000 claims description 2
- 108010061212 tubulysin D Proteins 0.000 claims description 2
- SAJNCFZAPSBQTQ-UHFFFAOYSA-N tubulysin D Natural products N=1C(C(=O)NC(CC(C)C(O)=O)CC=2C=CC=CC=2)=CSC=1C(OC(C)=O)CC(C(C)C)N(COC(=O)CC(C)C)C(=O)C(C(C)CC)NC(=O)C1CCCCN1C SAJNCFZAPSBQTQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 2
- 125000003712 glycosamine group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 71
- 241000699670 Mus sp. Species 0.000 description 52
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 51
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 41
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 125000005647 linker group Chemical group 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 210000000056 organ Anatomy 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 17
- 239000002904 solvent Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000002354 daily effect Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000011503 in vivo imaging Methods 0.000 description 12
- 238000004007 reversed phase HPLC Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 11
- 239000005695 Ammonium acetate Substances 0.000 description 11
- 0 C[C@](C(N(CC(*)(*)C1)[C@]1*#C)=O)NC(c1c(*)c(*)nc(CNC=C)c1*)=O Chemical compound C[C@](C(N(CC(*)(*)C1)[C@]1*#C)=O)NC(c1c(*)c(*)nc(CNC=C)c1*)=O 0.000 description 11
- 229940043376 ammonium acetate Drugs 0.000 description 11
- 235000019257 ammonium acetate Nutrition 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000007821 HATU Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Chemical group 0.000 description 7
- 239000012300 argon atmosphere Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 229940125773 compound 10 Drugs 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- LKKIBSZFPLXREY-LYWCUUMRSA-N [[(1r,3r)-1-acetyloxy-4-methyl-1-[4-[[(2r,4s)-4-methyl-1-(4-methylphenyl)-5-oxo-5-[2-[2-(pyridin-4-yldisulfanyl)ethoxycarbonyl]hydrazinyl]pentan-2-yl]carbamoyl]-1,3-thiazol-2-yl]pentan-3-yl]-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]p Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(=O)NNC(=O)OCCSSC=1C=CN=CC=1)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C LKKIBSZFPLXREY-LYWCUUMRSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 150000001412 amines Chemical group 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 229940014144 folate Drugs 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- 235000019152 folic acid Nutrition 0.000 description 5
- 239000011724 folic acid Substances 0.000 description 5
- 150000002337 glycosamines Chemical group 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 4
- 108010013639 Peptidoglycan Proteins 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 3
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 3
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical compound NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 238000011717 athymic nude mouse Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 3
- 239000001022 rhodamine dye Substances 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- QEPWHIXHJNNGLU-KRWDZBQOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 QEPWHIXHJNNGLU-KRWDZBQOSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QZQXRZXYWVQWAY-UHFFFAOYSA-N 8-(9h-fluoren-9-ylmethoxycarbonylamino)octanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCCCCCC(=O)O)C3=CC=CC=C3C2=C1 QZQXRZXYWVQWAY-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 108010085443 Anserine Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000210053 Potentilla elegans Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229950006137 dexfosfoserine Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VQTBINYMFPKLQD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(3-hydroxy-6-oxoxanthen-9-yl)benzoate Chemical compound C=12C=CC(=O)C=C2OC2=CC(O)=CC=C2C=1C1=CC=CC=C1C(=O)ON1C(=O)CCC1=O VQTBINYMFPKLQD-UHFFFAOYSA-N 0.000 description 1
- TZHBAZVSQWVUOB-REOHCLBHSA-N (2r)-3-sulfanyl-2-(sulfoamino)propanoic acid Chemical compound OC(=O)[C@H](CS)NS(O)(=O)=O TZHBAZVSQWVUOB-REOHCLBHSA-N 0.000 description 1
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 1
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 1
- ILRYLPWNYFXEMH-CRCLSJGQSA-N (2s)-2-azaniumyl-4-[(2s)-2-azaniumyl-2-carboxylatoethyl]sulfanylbutanoate Chemical compound OC(=O)[C@@H](N)CCSC[C@@H](N)C(O)=O ILRYLPWNYFXEMH-CRCLSJGQSA-N 0.000 description 1
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- PCLMSUBZTGCHQT-WCBMZHEXSA-N (2s,4r)-4-amino-5-(4-hydroxyphenyl)-2-methylpentanoic acid Chemical compound OC(=O)[C@@H](C)C[C@@H](N)CC1=CC=C(O)C=C1 PCLMSUBZTGCHQT-WCBMZHEXSA-N 0.000 description 1
- TVHNWAKCVXFPNB-HCCKASOXSA-N (4r)-4-amino-2-methyl-5-phenylpentanoic acid Chemical compound OC(=O)C(C)C[C@@H](N)CC1=CC=CC=C1 TVHNWAKCVXFPNB-HCCKASOXSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- YOAWSYSKQHLFPM-UHFFFAOYSA-N 5-amino-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(N)C=C21 YOAWSYSKQHLFPM-UHFFFAOYSA-N 0.000 description 1
- GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- ULNYIWGOTRMHNN-JGKLOMJBSA-N CCCC(OCN([C@H](CCc1nc(C(N[C@H](C[C@H](C)C(C)=O)Cc(cc2)ccc2O)=O)c[s]1)C(C)C)C([C@H](/C(/C)=C/C)NC([C@@H]1N(C)CCCC1)=O)=O)=O Chemical compound CCCC(OCN([C@H](CCc1nc(C(N[C@H](C[C@H](C)C(C)=O)Cc(cc2)ccc2O)=O)c[s]1)C(C)C)C([C@H](/C(/C)=C/C)NC([C@@H]1N(C)CCCC1)=O)=O)=O ULNYIWGOTRMHNN-JGKLOMJBSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 210000005131 Hürthle cell Anatomy 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BPSLZWSRHTULGU-UHFFFAOYSA-N Methylpipecolic acid Chemical compound CN1CCCCC1C(O)=O BPSLZWSRHTULGU-UHFFFAOYSA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OVWNDXVBHKBRLZ-UHFFFAOYSA-N NC(CNN)C(NC(CC(O)=O)C1OC1NC(CS)C(O)=O)=O Chemical compound NC(CNN)C(NC(CC(O)=O)C1OC1NC(CS)C(O)=O)=O OVWNDXVBHKBRLZ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035603 Pleural mesothelioma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000000228 antimanic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004479 myeloid suppressor cell Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- SJYQYOVTHISIKX-UHFFFAOYSA-N n,n-dimethylformamide;n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CN(C)C=O.CCN(C(C)C)C(C)C SJYQYOVTHISIKX-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- BZSPLYKPHSEUHY-UHFFFAOYSA-N tin(2+) hydrochloride Chemical compound Cl.[Sn+2] BZSPLYKPHSEUHY-UHFFFAOYSA-N 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
Definitions
- the present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient and, in some embodiments, to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient.
- CAFs cancer-associated fibroblasts
- the present teachings also relate to conjugates and methods for therapeutically treating cancer cells and/or CAFs in a patient.
- tumors include infiltrating immune and inflammatory cells such as T cells, tumor associated macrophages, myeloid-suppressor cells, cancer associated fibroblasts (CAF), blood and lymphatic vasculature networks, and
- ECM extracellular matrix
- CAFs are one of the major type of cells present in the tumor microenvironment and play a role in secretion of many chemokines, cytokines, growth factor, along with modification and degradation of ECM.
- CAFs overexpress fibroblast activation protein alpha (FAP) which has a limited expression on the healthy cells.
- FAP fibroblast activation protein alpha
- FAP is a type II membrane integral protein which belongs to a larger family of proteases which are capable of cleaving the proline-amino acid peptide bond. Other members of the same family are dipeptidyl peptidase IV (DPPIV) and proyloligopeptidase (POP). FAP exhibits both endo and exopeptidase activity. FAP is primarily found to be localized on the cell surface but a soluble form of the protein in human plasma has also been reported. FAP exists as a homodimer. FAP is found to be expressed in CAFs of more than 90% of the epithelial solid tumors, tissues involved in wound healing, and remodeling.
- DPPIV dipeptidyl peptidase IV
- POP proyloligopeptidase
- B comprises a fibroblast activation protein (FAP) inhibitor
- L comprises a bivalent linker
- X comprises a near infrared (NIR) dye, a radioactive imaging agent, or a therapeutic agent effective against cancer cells and/or cancer-associated fibroblasts (CAF).
- NIR near infrared
- CAF cancer-associated fibroblasts
- R 1 and R 2" are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Q-C 4 alkyl;
- R is a Ci-C 4 alkyl, nitrile, or isonitrile
- R 4 , R 5 , and R 6 are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Q-C 4 alkyl;
- n is an integer from 1 to 8.
- linker comprises at least one amino acid in the D- or reconfiguration, or a derivative thereof, selected from the group consisting of Lys, Asn, Thr, Ser, He, Met, Pro, His, Gin, Arg, Gly, Asp, Glu, Ala, Val, Phe, Leu, Tyr, Cys, and Trp.
- m is an integer from 0 to 9
- p is an integer from 3 to 10
- q is an integer from 3 to 100.
- each of R 7 and R 8 is independently H or C r C 6 alkyl
- t is an integer from 1 to 8.
- R 6 is H or Ci-C 6 alkyl.
- L comprises a bivalent linker
- X comprises a near infrared (NIR) dye.
- a method of surgically removing cancer-associated fibroblasts (CAFs) from a patient comprising:
- L comprises a bivalent linker and X comprises a near infrared (NIR) dye
- A is a drug selected from the group consisting of a vinca alkaloid, a cryptophycin, bortezomib, thiobortezomib, a tubulysin, aminopterin, rapamycin, paclitaxel, docetaxel, doxorubicin, daunorubicin, everolimus, a-amanatin, verucarin, didemnin B, geldanomycin, purvalanol A, ispinesib, budesonide, dasatinib, an epothilone, a maytansine, and a tyrosine kinase inhibitor.
- A is a drug selected from the group consisting of a vinca alkaloid, a cryptophycin, bortezomib, thiobortezomib, a tubulysin, aminopterin, rapamycin, paclitaxel, docetaxel,
- R la , R 3a , R 3a and R 3a are each independently selected from the group consisting of H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 _C 6 alkynyl and C 3 _C 6 cycloalkyl, wherein each hyd: atom in Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 _C 6 alkynyl and C 3 _C 6 cycloalkyl is independently optionally substituted by halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 _C 6 alkynyl, C 3 _C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, 5- to 7-membered heteroaryl, -OR 13a , - OC(0)R 13a , -OC(0)NR 13a R 13a' , -OS(0)
- R 2a , R 4a and R 12a are each independently selected from the group consisting of H,
- Ci-C 6 alkyl C 2 -C 6 alkenyl, C 2 _C 6 alkynyl;
- R 5a and R 6a are each independently selected from the group consisting of H, halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -OR 15a , -SR 15a and -NR 15a R 15a' , wherein each hydrogen atom in Ci-C 6 alkyl, C 2 -C 6 alkenyl and C 2 _C 6 alkynyl is independently optionally substituted by halogen, -OR 16a , -SR 16a , -NR 16a R 16a' , -C(0)R 16a , -C(0)OR 16a or -C(0)NR 16a R 16a ; or R 5a and R 6a taken together with the carbon atom to which they are attached form a -C(O)-;
- each R 7a , R 8a , R 9a , R 10a and R lla is independently selected from the group consisting of H, halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 _C 6 alkynyl, -CN, -N0 2 , -NCO, -OR 17a , -SR 17a , -S(0) 2 OR 17a , -NR 17a R 17a' , -P(0)(OR 17a ) 2 , -C(0)R 17a , -C(0)OR 17a and -C(0)NR 17a R 17a' , wherein each hydrogen atom in Ci-C 6 alkyl, C 2 -C 6 alkenyl and C 2- C 6 alkynyl is independently optionally substituted by halogen, -OR 18a , -SR 18a , -NR 18a R 18a' , -C(0)R 18a , -C(0)OR 18a
- each R 13a , R 13a' , R 14a , R 14a' , R 15a , R 15a' , R 16a , R 16a' , R 17a and R 17a' is independently selected from the group consisting of H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in Ci-C 7 alkyl, C 2 -C 7 alkenyl, C 2 _C 7 alkynyl, C 3 _C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH,
- each R 18a and R 18a' is independently selected from the group consisting of H, C ⁇ -
- each R 19a is independently selected from H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 _C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl and 5- to 7- membered heteroaryl; and 0077] a is 1, 2 or 3.
- R la , R 3a , R 3a and R 3a are each independently selected from the group consisting of H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and C 3 _C 6 cycloalkyl, wherein each hydrogen atom in Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and C 3 _C 6 cycloalkyl is independently optionally substituted by halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, 5- to 7-membered heteroaryl, -OR 13a , - OC(0)R 13a , -OC(0)NR 13a R 13a' , -OS(0)R 13a ,
- R 2a , R 4a and R 12a are each independently selected from the group consisting of H,
- Ci-C 6 alkyl C 2 -C 6 alkenyl, C 2 -C 6 alkynyl;
- R 5a is selected from the group consisting of H, halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -OR 15a , -SR 15a and -NR 15a R 15a' , wherein each hydrogen atom in Ci-C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl is independently optionally substituted by halogen, - OR 16a , -SR 16a , -NR 16a R 16a' , -C(0)R 16a , -C(0)OR 16a or -C(0)NR 16a R 16a' ;
- each R 7a , R 8a , R 9a , R 10a and R lla is independently selected from the group consisting of H, halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -CN, -N0 2 , -NCO, -OR 17a , -SR 17a , -S(0) 2 OR 17a , -NR 17a R 17a' , -P(0)(OR 17a ) 2 , -C(0)R 17a , -C(0)OR 17a and -C(0)NR 17a R 17a' , wherein each hydrogen atom in Q-C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl is independently optionally substituted by halogen, -OR 18a , -SR 18a , -NR 18a R 18a' , -C(0)R 18a , -C(0)OR
- each R 13a , R 13a' , R 14a , R 14a' , R 15a , R 15a' , R 16a , R 16a' , R 17a and R 17a' is independently selected from the group consisting of H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 _C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in Q-G7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 _C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH,
- each R and R is independently selected from the group consisting of H, C ⁇ -
- each R 19a is independently selected from H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl and 5- to 7- membered heteroaryl; and
- a is 1, 2 or 3.
- R 9a is selected from the group consisting of H, halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -CN, -N0 2 , -NCO, -OR 17a , -SR 17a , -S(0) 2 OR 17a , -NR 17a R 17a' , - P(0)(OR 17a ) 2 , -C(0)R 17a , -C(0)OR 17a and -C(0)NR 17a R 17a' , wherein each hydrogen atom in d- C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl is independently optionally substituted by halogen, - OR 18a , -SR 18a , -NR 18a R 18a' , -C(0)R 18a , -C(0)OR 18a or -C(0)NR 18a R 18a' ;
- each R 13a , R 17a and R 17a is independently selected from the group consisting of
- heterocycloalkyl C 6 -Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 _C 6 cycloalkyl, 3- to 7-membered
- heterocycloalkyl, C 6 -Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH, -NH 2 or -C0 2 H;
- each R and R is independently selected from the group consisting of H, Ci-
- each R 19a is independently selected from H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl and 5- to 7- membered heteroaryl.
- a pharmaceutical composition comprising a conjugate of any of the preceding clauses, or a pharmaceutically acceptable salt thereof, and optionally at least one pharmaceutically acceptable excipient.
- a method of treating cancer in a subject comprising,
- [00112] 58 A conjugate according to any one of clause 1 to 23, 38 to 47 or 51, or a pharmaceutically acceptable salt thereof, for use in a method of treating FAP expressing cancer in a subject.
- a method of imaging a population of cells in vitro comprising
- FIG. 1 shows the chemical structure and an LC/MS trace for Compound 3.
- FIG. 2 shows the chemical structure and an LC/MS trace for Compound 4.
- FIG. 3 shows the chemical structure and an LC/MS trace for Compound 5.
- FIG. 4 shows the chemical structure and an LC/MS trace for Compound 7.
- FIG. 5 shows the chemical structure and an LC/MS trace for Compound 8 (JFL).
- FIG. 6 shows the chemical structure and an LC/MS trace for Compound 10.
- FIG. 7 shows the chemical structure and an LC/MS trace for JFL-L1.
- FIG. 8 shows the chemical structure and an LC/MS trace for JFL-L1-FM.
- FIG. 9 shows the chemical structure and an LC/MS trace for S0456 maleimide.
- FIG. 10 shows the chemical structure and an LC/MS trace for JFL-L1-S0456.
- Figure 11 shows in vitro confocal imaging results with JFL-L1-FM.
- Figure 12 shows in vitro binding affinity of JFL-L1-S0456FAP transfected HEK293 cells as determined by fluorescence vs. concentration.
- Figure 13 shows in vivo imaging of JFL-L1-S0456 in FaDu mouse xenografts.
- Figure 14 shows in vivo imaging of JFL-L1-S0456 in KB mouse xenografts.
- Figure 15 shows in vivo imaging of JFL-L1-S0456 in HT29 mouse xenografts.
- Figure 16 shows in vivo imaging of JFL-L1-S0456 in MDA-MB231 mouse xenografts.
- Figure 17 shows the LC/MS trace for JFL-Ll-TubBH.
- Figure 18A shows tumor volume over time in response to treatment with JFL-Ll- TubBH and Figure 18B shows body weight of the mice used in the experiment.
- A Control;
- ⁇ FAP-competition;
- - Consecutive days - FAP-TubBH (40 nmoles);
- ⁇ daily FAP-TubBH (40 nmoles).
- Figure 19A shows tumor volume over time in response to JFL-Ll-TubBH and JFL-Ll-TubBH in combination with other treatments
- Figure 19B shows the body weight of the mice used in the experiment.
- o FAP-TubBH & Folate- PI3K.
- Figure 20A shows tumor volume over tie in response to JFL-L1-FM and Figure 20B shows the body weight of the mice used in the experiment, (o) Control; ( ⁇ ) FAP-FM; ( ⁇ ) FAP-competition.
- Figure 21A-B shows the LC/MS trace for JFL-L2-S0456.
- Figures 22A-C show in vivo imaging with JFL-L2-S0456.
- Figure 23 shows in vivo imaging using different concentrations of JFL-L1-S0456.
- Figures 24A-B show Cocktail Imaging: FAPa and LHRH-R targeted NIR conjugates.
- Figures 25A-B show the LC/MS traces for JFL-L3.
- Figure 26 shows in vitro binding affinity of JFL-L3.
- Figures 27A-C show in vivo imaging of JFL-L3
- B comprises a fibroblast activation protein (FAP) inhibitor
- L comprises a bivalent linker
- X comprises a near infrared (NIR) dye, a radioactive imaging agent, or a therapeutic agent effective against cancer cells and/or cancer- associated fibroblasts (CAF).
- NIR near infrared
- CAF cancer-associated fibroblasts
- R 1 and R 2 are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Ci-C 4 alkyl;
- R is a Ci-C 4 alkyl, nitrile, or isonitrile;
- R 4 , R 5 , and R 6 are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Ci-C 4 alkyl.
- L comprises a bivalent linker
- X comprises a near infrared (NIR)
- a method of surgically removing cancer-associated fibroblasts (CAFs) from a patient comprising:
- the tumor microenvironment com rising at least one CAF, the conjugate having a structure
- L comprises a bivalent linker and X comprises a near infrared (NIR) dye; causing the NIR dye to fluoresce through an application of an optical stimulus thereto; and cutting CAF-containing tissue of the patient based on a result of the fluorescence.
- NIR near infrared
- the formulae include and represent not only all pharmaceutically acceptable salts of the conjugates, but also include any and all hydrates and/or solvates of the conjugate formulae. It is appreciated that certain functional groups, such as the hydroxy, amino, and like groups form complexes and/or coordination conjugates with water and/or various solvents, in the various physical forms of the conjugates. Accordingly, the above formulae are to be understood to include and represent those various hydrates and/or solvates. It is also to be understood that the non-hydrates and/or non-solvates of the conjugate formulae are described by such formula, as well as the hydrates and/or solvates of the conjugate formulae.
- Ci-C 4 alkyl refers to a straight, branched or cyclic hydrocarbon chain containing from 1 to 4 carbon atoms.
- Representative examples of Ci-C 4 alkyl groups in accordance with the present teachings include but are not limited to methyl, ethyl, propyl, z ' so-propyl, cyclopropyl, butyl, z ' so-butyl, ieri-butyl, sec-butyl, and cyclobutyl.
- halogen refers to fluorine, chlorine, iodine or bromine.
- amino acid means any molecule that includes an alpha-carbon atom covalently bonded to an amino group and an acid group.
- the acid group may include a carboxyl group.
- amino acid may include molecules having one of the formulas:
- amino acid includes stereoisomers such as the D-amino acid and L-amino acid forms.
- Illustrative amino acid groups include, but are not limited to, the twenty endogenous human amino acids and their derivatives, such as lysine (Lys), asparagine (Asn), threonine (Thr), serine (Ser), isoleucine (He), methionine (Met), proline (Pro), histidine (His), glutamine (Gin), arginine (Arg), glycine (Gly), aspartic acid (Asp), glutamic acid (Glu), alanine (Ala), valine (Val), phenylalanine (Phe), leucine (Leu), tyrosine (Tyr), cysteine (Cys), tryptophan (Trp), phosphoserine (PSER), sul
- amino acids can be covalently attached to other portions of the conjugates described herein through their alpha-amino and carboxy functional groups (i.e. in a peptide bond configuration), or through their side chain functional groups (such as the side chain carboxy group in glutamic acid) and either their alpha-amino or carboxy functional groups. It will be understood that amino acids, when used in connection with the conjugates described herein, may exist as zwitterions in a conjugate in which they are incorporated.
- a derivative of an amino acid includes an amino acid that includes a substituent on the side-chain that is not present on a natural amino acid. Some examples of derivatives are provided above.
- a derivative of glutamic acids includes the covalent attachment of an amine substituent through the carboxylic acid on the glutamic acid side-chain to form an amide bond.
- the amine substituent is an amino sugar, such as 1-deoxy-l-amino-D-glucitol as shown below.
- the phrase "therapeutically effective amount” refers to an amount of a drug or pharmaceutical agent that elicits the biological or medicinal response in a subject (i.e. a tissue system, animal or human) that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes, but is not limited to, alleviation of the symptoms of the disease or disorder being treated.
- the therapeutically effective amount is that amount of an active which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment.
- the therapeutically effective amount is that amount of an inactive prodrug which when converted through normal metabolic processes to produce an amount of active drug capable of eliciting the biological or medicinal response in a subject that is being sought.
- the dose is advantageously selected with reference to any toxicity, or other undesirable side effect, that might occur during administration of one or more of the conjugates described herein.
- the co-therapies described herein may allow for the administration of lower doses of conjugates that show such toxicity, or other undesirable side effect, where those lower doses are below thresholds of toxicity or lower in the therapeutic window than would otherwise be administered in the absence of a cotherapy.
- administering includes all means of introducing the conjugates and compositions described herein to the host animal, including, but are not limited to, oral (po), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, inhalation, buccal, ocular, sublingual, vaginal, rectal, and the like.
- the conjugates and compositions described herein may be administered in unit dosage forms and/or formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants, and/or vehicles.
- composition refers to a mixture of one or more of the conjugates in accordance with the present teachings, or pharmaceutically acceptable salts, solvates, hydrates thereof, with other chemical components, such as pharmaceutically acceptable excipients.
- the purpose of a pharmaceutical composition is to facilitate administration of a conjugate to a subject.
- Pharmaceutical compositions suitable for the delivery of conjugates in accordance with the present teachings and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
- a conjugate in accordance with the present teachings includes an imaging agent, such as a near infrared (NIR) dye or a radioactive imaging agent.
- imaging agents such as a near infrared (NIR) dye or a radioactive imaging agent.
- NIR near infrared
- Representative compounds that may be used as imaging agents in accordance with the present teachings include but are not limited to dyes ⁇ e.g., rhodamine dyes, cyanine dyes, fluorescein dyes, etc.), PET imaging agents, radiolabeled agents, and the like.
- rhodamine dyes include but are not limited to 5-carboxytetramethylrhodamine (5-TAMRA), rhodamine B, rhodamine 6G, TRITC, Texas Red, rhodamine 123, sulforhodamine 101, and the like.
- fluorescein dyes include but are not limited to fluorescein, fluorescein maleimide (FM), 5 -amino-fluorescein, 6-amino-fluorescein, fluorescein isocyanate (FITC), NHS -fluorescein, Oregon Green, Tokyo Green, Singapore Green, Philadelphia Green, and the like.
- Representative near infrared dyes that may be used in accordance with the present teachings include but are not limited to LS288, IR800, SP054, S0121, KODAK, IRD28, S2076, S0456, and derivatives thereof.
- a radiolabeled agent may be used as an imaging agent in accordance with the present teachings.
- a rhodamine dye or fluorescein dye may be isotopically labelled.
- isotopes suitable for inclusion in the conjugates include isotopes of hydrogen (e.g., 2 H and 3 H), carbon (e.g., 11 C, 13 C, and 14 C), chlorine (e.g., 36 C1), fluorine (e.g., 18 F), iodine (e.g., 123 I and 125 I), nitrogen (e.g., 13 N and 15 N), oxygen (e.g., 15 0, 17 0, and 18 0), phosphorus (e.g., 32 P), and sulfur (e.g., 35 S).
- hydrogen e.g., 2 H and 3 H
- carbon e.g., 11 C, 13 C, and 14 C
- chlorine e.g., 36 C1
- fluorine e.g., 18 F
- Radioactive isotopes tritium (i.e., 3 H), and carbon- 14 (i.e., 14 C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Isotopically-labeled conjugates may generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagents in place of the non- labeled reagent previously employed.
- in vitro imaging methods described herein may include (a) contacting a population of cells with a conjugate in accordance with the present teachings that is suitable for imaging to provide the conjugate bound to cells expressing a FAP protein, and (b) visualizing the conjugate bound to cells by irradiation with light. It will be appreciated that visualizing the conjugate bound to cells by irradiation with light may include irradiation at an excitation wavelength and detection at an emission wavelength.
- in vitro imaging methods described herein may include (a) contacting a population of cells with a conjugate in accordance with the present teachings that is suitable for imaging to provide the conjugate bound to cells expressing a FAP protein, (b) irradiating the conjugate bound to cells expressing a FAP protein with an excitation wavelength light, and (c) detecting light emitted from the cancer cells at an emission wavelength.
- tissues such as cancerous tumors
- in vivo imaging methods in accordance with the present teachings may include (a) administering to the patient a conjugate in accordance with the present teachings that is suitable for imaging; or a pharmaceutically acceptable salt thereof, to provide the conjugate bound to cells expressing a FAP protein; and (b) visualizing the conjugate bound to cells expressing a FAP protein by irradiation with light.
- visualizing the conjugate bound to cells by irradiation with light may include irradiation at an excitation wavelength and detection at an emission wavelength.
- in vivo imaging methods described herein may include (a) administering to the patient a conjugate as described herein that is suitable for imaging; or a pharmaceutically acceptable salt thereof, to provide the conjugate bound to cells expressing a FAP protein; (b) irradiating the conjugate bound to cells expressing a FAP protein with an excitation wavelength light; and (c) detecting light emitted from the cancer cells at an emission wavelength.
- visualizing the conjugate bound to cells by irradiation with light may be carried out using any known imaging techniques (diagnostic or otherwise) or instrumentation known in the art.
- a conjugate in accordance with the present teachings includes a therapeutic agent which, in some embodiments, is therapeutically effective against cancer cells and/or cancer-associated fibroblast (CAFs).
- the therapeutic agent used in accordance with the present teachings may be any molecule capable of modulating or otherwise modifying cell function, including pharmaceutically active compounds (e.g. , a therapeutic agent), or any molecule capable of providing a measurable signal for imaging or visualized cells or tissues (e.g. , an imaging agent).
- Suitable molecules that may be useful as therapeutic agents include but are not limited to peptides, oligopeptides, retro-inverso oligopeptides, proteins, protein analogs in which at least one non-peptide linkage replaces a peptide linkage, apoproteins, glycoproteins, enzymes, coenzymes, enzyme inhibitors, amino acids and their derivatives, receptors and other membrane proteins; antigens and antibodies thereto; haptens and antibodies thereto; hormones, lipids, phospholipids, liposomes; toxins; antibiotics; analgesics; bronchodilators; beta-blockers; antimicrobial agents; antihypertensive agents; cardiovascular agents including antiarrhythmics, cardiac glycosides, antianginals and vasodilators; central nervous system agents including stimulants, psychotropics, antimanics, and depressants; antiviral agents; antihistamines; cancer drugs including chemotherapeutic agents; tranquilizers; anti-depressants;
- the therapeutic agent may be a tubulysin.
- Natural tubulysins are generally linear tetrapeptides consisting of N-methyl pipecolic acid (Mep), isoleucine (He), an unnatural aminoacid called tubuvaline (Tuv), and either an unnatural aminoacid called tubutyrosine (Tut, an analog of tyrosine) or an unnatural aminoacid called tubuphenylalanine (Tup, an analog of phenylalanine).
- the therapeutic agent is a tetrapeptide of the formula
- R la , R 3a , R 3a and R 3a are each independently selected from the group consisting of H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and C 3 _C 6 cycloalkyl, wherein each hydrogen atom in Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and C 3 -C 6 cycloalkyl is
- R 2a , R 4a and R 12a are each independently selected from the group consisting of H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl;
- R 5a and R 6a are each independently selected from the group consisting of H, halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 _C 6 alkynyl, -OR 15a , -SR 15a and -NR 15a R 15a' , wherein each hydrogen atom in Ci-C 6 alkyl, C 2 -C 6 alkenyl and C 2 C 6 alkynyl is independently optionally substituted by halogen, -OR 16a , -SR 16a , -NR 16a R 16a' , -C(0)R 16a , -C(0)OR 16a or -C(0)NR 16a R 16a ; or R 5a and R 6a taken together with the carbon atom to which they are attached form a -C(O)-;
- each R 7a , R 8a , R 9a , R 10a and R lla is independently selected from the group consisting of H, halogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -CN, -N0 2 , -NCO, -OR 17a , -SR 17a , -S(0) 2 OR 17a , -NR 17a R 17a' , -P(0)(OR 17a ) 2 , -C(0)R 17a , -C(0)OR 17a and -C(0)NR 17a R 17a' , wherein each hydrogen atom in Ci-C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl is independently optionally substituted by halogen, -OR 18a , -SR 18a , -NR 18a R 18a' , -C(0)R 18a , -C(0)OR
- each R 13a , R 13a' , R 14a , R 14a' , R 15a , R 15a' , R 16a , R 16a' , R 17a and R 17a' is independently selected from the group consisting of H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 _C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C7 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH
- R and R is independently selected from the group consisting of H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 - C 10 aryl, 5- to 7-membered heteroaryl -C(0)R 19a , -P(0)(OR 19a ) 2 , and -S(0) 2 OR 19a ,
- each R 19 is independently selected from H, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl and 5- to 7- membered heteroaryl;
- a is 1, 2 or 3;
- the therapeutic agent is of the formula
- R la , R 2a , R 3a , R 3a' , R 3a" ,R 4a , R 5a , R 7a , R 8a , R 9a , R 10a , R l la and R 12a are as described herein, and * represents a covalent bond to the rest of the conjugate.
- the therapeutic agent may be a naturally occurring tubulysin, or analog or derivative thereof, of the following general formula
- R a and R a are as described herein, and * represents a covalent bond to the rest of the conjugate.
- the therapeutic agent may be a naturally occurring tubulysin of the following general formula
- the methods in accordance with the present teachings may be used for both human clinical medicine and veterinary applications as a "subject".
- a "subject" may be administered the conjugates in accordance with the present teachings, and may be human ("patient") or, in the case of veterinary applications, may be a laboratory, agricultural, domestic, or wild animal.
- the subject may be a human patient, a laboratory animal such as a rodent (e.g.
- mice, rats, hamsters, etc. mice, rats, hamsters, etc.
- a rabbit, a monkey, a chimpanzee domestic animals such as dogs, cats, and rabbits
- agricultural animals such as cows, horses, pigs, sheep, goats, and wild animals in captivity such as bears, pandas, lions, tigers, leopards, elephants, zebras, giraffes, gorillas, dolphins, and whales.
- the cancers described herein may be a cancer cell population that is tumorigenic, including benign tumors and malignant tumors, or the cancer may be non-tumorigenic.
- the cancer may arise spontaneously or by such processes as mutations present in the germline of the patient or somatic mutations, or the cancer may be chemically-, virally-, or radiation-induced.
- Cancers applicable to the present teachings include but are not limited to a carcinoma, a sarcoma, a lymphoma, a melanoma, a mesothelioma, a nasopharyngeal carcinoma, a leukemia, an adenocarcinoma, and a myeloma.
- the cancers may be lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head, cancer of the neck, cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer, endometrial cancer, leiomyosarcoma, rectal cancer, stomach cancer, colon cancer, breast cancer, triple negative breast cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, non-small cell lung cancer, small cell lung cancer, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic leukemia, acute leukemia, lymphocytic lymphomas, pleural mesotheli
- cholangiocarcinoma cholangiocarcinoma, Hurthle cell thyroid cancer or adenocarcinoma of the gastroesophageal junction.
- compositions in accordance with the present teachings include acid addition and base salts thereof.
- Suitable acid addition salts are formed from acids which form non-toxic salts.
- Illustrative examples include but are not limited to the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate
- Suitable base salts of the conjugates described herein are formed from bases which form non-toxic salts.
- Illustrative examples include but are not limited to the arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
- Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
- conjugates in accordance with the present teachings may be administered as a formulation in association with one or more pharmaceutically acceptable carriers.
- the carriers may be excipients.
- the choice of carrier may depend on factors such as the particular mode of administration, the effect of the carrier on solubility and stability, and the nature of the dosage form.
- Pharmaceutical compositions suitable for the delivery of conjugates as described herein and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington: The Science & Practice of Pharmacy, 21th Edition (Lippincott Williams &
- a pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, and combinations thereof, that are physiologically compatible.
- the carrier is suitable for parenteral administration.
- Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Supplementary active compounds may also be incorporated into compositions of the invention.
- liquid formulations may include suspensions and solutions.
- Such formulations may comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose or a suitable oil, and one or more emulsifying agents and/or suspending agents.
- Liquid formulations may also be prepared by the reconstitution of a solid.
- an aqueous suspension may contain the active materials in admixture with appropriate excipients.
- excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally-occurring phosphatide, for example, lecithin; a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example,
- aqueous suspensions may also contain one or more preservatives, for example, ascorbic acid, ethyl, n-propyl, or p- hydroxybenzoate; or one or more coloring agents.
- dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Additional excipients, for example, coloring agents, may also be present.
- Suitable emulsifying agents may be naturally-occurring gums, for example, gum acacia or gum tragacanth; naturally-occurring phosphatides, for example, soybean lecithin; and esters including partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan mono-oleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride may be included in the composition.
- Prolonged absorption of injectable compositions may be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin.
- Illustrative formats for oral administration include but are not limited to tablets, capsules, elixirs, syrups, and the like.
- the route of administration and/or whether the conjugates are administered locally or systemically a wide range of permissible dosages are contemplated herein, including doses falling in the range from about 1 ⁇ g/kg to about 1 g/kg.
- the dosages may be single or divided, and may administered according to a wide variety of protocols, including q.d., b.i.d., t.i.d., or even every other day, biweekly (b.i.w.), once a week, once a month, once a quarter, and the like.
- the therapeutically effective amounts described herein correspond to the instance of administration, or alternatively to the total daily, weekly, month, or quarterly dose, as determined by the dosing protocol.
- a conjugate in accordance with the present teachings may be administered directly into the blood stream, into muscle, or into an internal organ.
- suitable routes for such parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, epidural, intracerebroventricular, intraurethral, intrasternal, intracranial,
- Suitable means for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- parenteral formulations are typically aqueous solutions which may contain carriers or excipients such as salts, carbohydrates and buffering agents (preferably at a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyro gen-free water.
- a suitable vehicle such as sterile, pyro gen-free water.
- any of the liquid formulations described herein may be adapted for parenteral administration of the conjugates described herein.
- the preparation of parenteral formulations under sterile conditions for example, by lyophilization under sterile conditions, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art. In some
- solubility of a conjugate as described herein used in the preparation of a parenteral formulation may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
- formulations for parenteral administration may be formulated for immediate and/or modified release.
- active agents in accordance with the present teachings i.e. , the conjugates described herein may be
- the active agents may be prepared with carriers that will protect the conjugate against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers may be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PGLA). Methods for the preparation of such formulations are generally known to those skilled in the art.
- the conjugates in accordance with the present teachings or compositions comprising the conjugates may be continuously administered, where appropriate.
- kits are provided. If a combination of active conjugates as described herein is to be administered, two or more pharmaceutical compositions may be combined in the form of a kit suitable for sequential administration or co-administration of the compositions. Such a kit may include two or more separate pharmaceutical compositions, at least one of which contains a conjugate in accordance with the present teachings, and means for separately retaining the compositions, such as a container, divided bottle, or divided foil packet. In some embodiments, compositions comprising one or more conjugates as described herein, in containers having labels that provide instructions for use of the conjugates as described herein for patient selection and/or treatment are provided.
- the term "kit” refers to an assembly of materials that are used in performing a method in accordance with the present teachings.
- the components of the kit may be provided in packaged combination in the same or in separate containers, depending on their cross-reactivities and stabilities, and in liquid or in solid form.
- the amounts and proportions of components provided in the kit may be selected so as to provide optimum results for a particular application.
- the components to be administered e.g. , to a patient
- the components to be administered may be provided in separate physical forms (e.g. , a kit containing one or more compositions and one or more fluids)
- all of the components that are to be introduced to the patient may be provided together in one common physical form (e.g., one composition or one fluid).
- kits in accordance with the present teachings may be supplied in all manner of containers such that the activities of the different components are substantially preserved, while the components themselves are not substantially adsorbed or altered by the materials of the container.
- Suitable containers include but are not limited to ampoules, bottles, test tubes, vials, flasks, syringes, bags and envelopes (e.g., foil-lined), and the like.
- the containers may be formed of any suitable material including but not limited to glass, organic polymers (e.g., polycarbonate, polystyrene, polyethylene, polypropylene, etc.), ceramic, metal (e.g. , aluminum), metal alloys (e.g. , steel), cork, and the like.
- the containers may contain one or more access ports (e.g., for access via a needle), such as may be provided by a septum.
- access ports e.g., for access via a needle
- septum Preferred materials for septa include rubber and polymers including but not limited to, for example, polytetrafluoroethylene of the type sold under the trade name TEFLON by DuPont (Wilmington, Del.).
- the containers may contain two or more compartments separated by partitions or membranes that can be removed to allow mixing of the components.
- Kits in accordance with the present teachings may also be supplied with other items known in the art and/or which may be desirable from a commercial and user standpoint, including but not limited to instructions for adding the components of the kit to a heat exchange system.
- kits in accordance with the present invention may be printed (e.g. , on paper) and/or supplied in an electronic-readable medium (e.g., floppy disc, CD-ROM, DVD-ROM, zip disc, videotape, audio tape, etc.).
- instructions may be provided by directing a user to an Internet web site (e.g., specified by the manufacturer or distributor of the kit) and/or via electronic mail, text message, social media, and/or the like, and combinations thereof.
- sterile injectable solutions may be prepared by
- dispersions are prepared by incorporating the conjugate into a sterile vehicle which contains a dispersion medium and any additional ingredients of those described above.
- sterile powders for the preparation of sterile injectable solutions the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof, or the ingredients may be sterile-filtered together.
- the composition may be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.
- the carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- conjugates described herein may be administered as single doses, or the doses may be divided and administered as a multiple-dose daily regimen.
- a staggered regimen for example, one to five days per week may be used as an alternative to daily treatment, and for the purpose of the methods described herein, such intermittent or staggered daily regimen is considered to be equivalent to every day treatment and is contemplated.
- the patient is treated with multiple injections of a conjugate in accordance with the present teachings to treat the cancer.
- the patient is injected multiple times (e.g.
- a conjugate in accordance with the present teachings for example, at 12-72 hour intervals or at 48-72 hour intervals. Additional injections of a conjugate in accordance with the present teachings may be administered to the patient at an interval of days or months after the initial injections(s) and the additional injections may prevent recurrence of the cancer.
- any suitable course of therapy with the conjugates in accordance with the present teachings may be used.
- individual doses and dosage regimens are selected to provide a total dose administered during a month of about 15 mg.
- a conjugate in accordance with the present teachings is administered in a single daily dose administered five days a week, in weeks 1, 2, and 3 of each 4 week cycle, with no dose administered in week 4.
- a conjugate in accordance with the present teachings is administered in a single daily dose administered three days a week, of weeks 1, and 3 of each 4 week cycle, with no dose administered in weeks 2 and 4.
- a conjugate in accordance with the present teachings is administered biweekly on weeks 1 and 2 (i.e., on days 1, 4, 8, 11, of a 3-week cycle).
- a conjugate described herein is administered and once weekly on weeks 1 and 2 (i.e. , days 1 and 8 of a 3-week cycle).
- the unitary daily dosage of the conjugates in accordance with the present teachings may vary significantly depending on the patient condition, the cancer being treated, the route of administration of the conjugates described herein and tissue distribution, and the possibility of co-usage of other therapeutic treatments, such as radiation therapy or additional drugs in combination therapies.
- the effective amount to be administered to a patient is based on body surface area, mass, and physician assessment of patient condition.
- Therapeutically effective doses (also referred to herein as "therapeutically effective amounts”) may range, for example, from about 0.5 mg/m 2 to about 20.0 mg/m 2.
- the conjugates in accordance with the present teachings may contain one or more chiral centers, or may otherwise be capable of existing as multiple stereoisomers. Accordingly, it is to be understood that the present invention includes pure stereoisomers as well as mixtures of stereoisomers, such as enantiomers, diastereomers, and enantiomerically or
- the conjugates in accordance with the present teachings may be capable of existing as geometric isomers. Accordingly, it is to be understood that the present invention includes pure geometric isomers or mixtures of geometric isomers.
- conjugates in accordance with the present teachings may exist in unsolvated forms as well as solvated forms, including hydrated forms.
- the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention.
- the conjugates described herein may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- compositions and/or dosage forms for administration of a conjugate in accordance with the present teachings are prepared from a conjugate with a purity of at least about 90%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 99.5%.
- compositions and or dosage forms for administration of a conjugate in accordance with the present teachings are prepared from a conjugate with a purity of at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or at least 99.5%.
- the FAP-targeted imaging agents described herein allow the imaging of tumor microenvironment and can allow surgeons to dissect the CAFs cells through fluorescence- guided surgery.
- the imaging agents described herein in combination with other cancer cell targeted imaging agents can further enhance the outcome of the fluorescence-guided surgery by allowing surgeons to remove the CAFs cells of the tumor microenvironment which cannot be achieved by the cancer cell targeted imaging agents. This can also reduce the chances of tumor recurrence post-surgery due to leftover CAFs compared to imaging only with cancer cell targeted imaging agents.
- the agents and methods described herein may open the door for the fluorescence guided surgery of cancers in which the cancer cells themselves do not express the cancer associated antigens such as LHRH-R, folate receptor, PSMA, etc. but the CAFs supporting those cancers express FAP. Dissection of the cells of tumor microenvironment will further contribute to decreasing the recurrence of the cancer post-surgery.
- the cancer associated antigens such as LHRH-R, folate receptor, PSMA, etc.
- CAFs supporting those cancers express FAP.
- Dissection of the cells of tumor microenvironment will further contribute to decreasing the recurrence of the cancer post-surgery.
- the FAP-targeted near-infrared dye conjugates may be combined with other cancer cell targeted imaging agents to allow imaging both cancer cells and tumor
- the FAP-targeted near-infrared dye conjugates described herein may allow for high tumor penetration, low photo bleaching, and high signal to noise ratio in addition to the targeting specificity of FAP inhibitor.
- the dye conjugates may rapidly clear from the receptor negative tissues. Since FAP is expressed in CAFs of most solid tumors, FAP targeted NTR dyes may be used for imaging many types of cancers.
- Benzotriazol-l-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop), N,N-Dimethylmethanamide (DMF), N-ethyl-N-isopropylpropan-2-amine (DIPEA), isopropyl alcohol (IPA,) dichloromethane (DCM) and trifluoroacetic acid (TFA), 1,2- ethanedithiol, triisopropylsilane (TIPS), and all other chemical reagents were purchased from Sigma- Aldrich.
- Cell culture reagents such as rosewell park memorial institute medium 1640 (RPMI 1640) was purchased from GIBCO whereas fetal bovine serum (FBS), 1% penicillin- streptomycin, 2Mm glutamine were purchased from Life Technologies.
- Compound 8 was linked to a spacer and is designated herein as JFL-L1.
- the ligand was linked to the linker partially in solution phase and by standard solid phase peptide synthesis. This was then coupled with the maleimide derivatives of FM or S0456 to yield JFL- Ll-FM or JFL-L1-S0456 respectively.
- Intermediates and final conjugates were purified by HPLC and characterized by using LC/MS and UPLC.
- LCMS characterization of JFL-Ll-FM and JFL-L1-S0456 are as follows. LRMS-LC/MS (m/z): [M+H] + calcd for C 4 6H 39 F 2 N 7 Oi 3 S, 967.91; found 968. LRMS-LC/MS (m/z): [M+H] + calcd for CTsHssFiNioNasOiiSs, 1745.82.35; found 1747. LC/MS trace of JFL-Ll-FM is shown in Figure 8. LC -L1-S0456 is shown in Figure 9.
- Scheme 3 Synthesis of S0456 maleimide. Reagents and conditions: a) KOH, H 2 0, rt-100 °C; b) HATU, Anhy. DIPEA, Anhy. DMF, rt. LC/MS trace of S0456 maleimide is shown in Figure 10.
- FAP targeted tubulysin B hydrazide conjugate was synthesized as described below. Briefly, JFL-Ll was dissolved in argon purged HPLC grade water and adjusted to pH 7.0 using a NaHC0 3 saturated solution of the same water. Disulfide activated tubulysin B hydrazide(l eq) in THF was added to the reaction mixture and stirred at room temperature under argon atmosphere. The progress of the reaction was monitored by analytical LRMS- LCMS.
- JFL-L2-S0456 FAP targeting ligand (JFL) was conjugated with a PEG and a peptidoglycan molecule to synthesize JFL-L2. Briefly, JFL-L2 was synthesized by standard solid phase peptides synthesis and purified by RP-HPLC as shown in Fig. 21A.
- JFL-L3 Prior to radiolabeling with 99m Tc the JFL- L3 was formulated according to previously published procedure. Briefly, the 0.1 mg of. JFL- L3, 80 mg of sodium a-D-glucoheptonate, and 10 mg of tin (II) hydrochloride, were dissolved in argon purged water. The pH of the solution was adjusted to 6.8 +0.2 with sodium hydroxide or hydrochloric acid. The final volume was adjusted to 10 ml and then transferred to 10 vials containing 1 ml each of the above solution and lyophilized. The lyophilized powder was sealed in the vials under argon and stored at -20 °C.
- 99m Tc labelling of JFL-L3 Radiolabeling of the conjugate was performed according to the published procedure. Briefly, to a formulated vial of JFL-L3 1 ml of 99m Tc sodium pertechnetate was added and heated for - 18 min at 100 °C. The chelated solution was cooled to room temperature prior to using it for in vitro and in vivo studies. The chelation efficiency of the conjugates was confirmed by radio HPLC, as shown in Fig. 25B.
- the cancer cells FaDu, HT29, MDA-MB231, and KB cells were cultured in a medium consisting RPMI 1640, 10% FBS, 1% penicillin-streptomycin, 1 % 2 mM glutamine at 37°C in a 5% C02 and 95% humidified atmosphere.
- HEK 293 cells were transfected to generate HEK293-FAP.
- the FAP positive cells were cultured in DMEM medium supplemented with 2 ⁇ 1/ ⁇ 1 of puromycin, 10% FBS, 1% penicillin-streptomycin, 1 % 2 mM glutamine at 37°C in a 5% C02 and 95% humidified atmosphere.
- mice Animal Husbandry. 5-6 weeks old female athymic nu/nu mice were purchased from Harlan Laboratories. The animals had access to normal rodent chow and water ad libitum. The animals were housed in standard 12 h light-dark cycles. All animal procedures were approved by the Purdue Animal Care and Use Committee.
- Tumor imaging was initiated once the tumor volume reached between 200 mm 3 and 300 mm 3. Each tumor-bearing mouse was intravenously injected (via tail vein) with 10 nanomoles of fluorescence dye conjugate either in the presence or absence of a 100-fold excess of the unlabeled conjugate. Animals were euthanized two hours post injection using C0 2 and the images were acquired using Caliper IVIS Luminal II. After performing the whole body image, the organs of interest were harvested and imaged to inspect the accumulation of the
- the image acquisition parameters were as follows: i) lamp level- high, ii) excitation-745 nm, iii) emission-ICG, iv) binning (M) 4M, (v) f-stop- 4, (vi) FOV-12.5, (vii) acquisition time, 5 s.
- the cancer cells FaDU, HT29, MDA-MB231 and KB were investigated for the expression of FAP.
- the cancer cells were seeded on a confocal well plate and incubated with 100 nM of the FAP targeted FM conjugate (JFL-L1-FM) After 1 h incubation at 37 °C the cells were washed to remove any excess of the un were observed under confocal microscopy to investigate any uptake of the dye, as shown in Figure 11. In all the four cell types no uptake of dye conjugate was observed. This implied absence of FAP on these cancer cells.
- the FAP transfected HEK293 cells were plated on amine coated 24 well plate and incubated with various concentrations of the dye conjugate either in the presence or absence of excess of the FAP ligand JFL. After 1 h of incubation cells were washed to remove any excess of the unbound dye. The cells were dissolved in 1% SDS followed by quantification of cell bound fluorescence using a fluorimeter. To quantify the fluorescence, the samples were excited at 745 nm and measuring the emission of 790 nm.
- FAP mediated uptake of the dye conjugate was observed in all the tumor types and excess of JFL was able to compete the fluorescence in the tumor.
- necropsy was performed to harvest the organs and imaged, as shown in Figures 13C and 13D (FaDu), Figures 14C and 14D (KB), Figures 15C and 15D (HT29), and Figures 16C and 16D (MDA-MB231) (organs from top to bottom: tumor, heart, lungs, spleen, pancreas, muscle, stomach, small intestine, large intestine, liver, and kidney).
- a minimal or no uptake of the dye conjugate was observed in the liver and kidney.
- the uptake in these organs was not receptor mediated and was largely due to excretion of the conjugate via renal or hepatic route.
- the cancer cells are FAP negative the in vivo uptake of the NIR dye conjugate is expected to be as a consequence of accumulation in the cancer-associated fibroblast which are known to express FAP.
- the FAP-targeted dye conjugate showed FAP mediated uptake in the tumor.
- Other organs kidney and liver) showed either minimal or no uptake of the near-infrared dye conjugate.
- MDA-MB231 5-6 weeks old female nu/nu athymic nude mice were subcutaneously injected with 5 million breast cancer cells (MDA-MB-231) into their shoulders. Tumors were measured in two perpendicular directions either daily or every other day during the treatment with Vernier calipers, and their volumes were calculated as 0.5 x L x W , where L is the longest axis (in millimeters), and W is the axis perpendicular to L (in millimeters). Once the tumor volume reached ⁇ 100 mm the mice were randomly divided into various groups and the treatment was initiated. Dosing solutions were prepared in sterile saline and injected intravenously via tail vein.
- mice in control group were injected with sterile saline whereas mice in treatment arms were injected with 40 nmoles of JFL-Ll-TubBH either daily or every other day.
- mice in competition group were also administered with 100-fold excess of the FAP-targeted ligand conjugated to the linker (JFL-L1), as shown in Fig. 18A.
- Mice were weighed as a measure of gross toxicity at each dosing, as shown in Fig. 18B.
- mice in control and competition arm did not show any reduction in tumor volume.
- mice in control and competition arm mice were dosed with 40nmoles of JFL-Ll-TubBH and divided into two separate groups depending on the frequency of the administration of the therapeutic agents.
- mice in both the therapy groups showed significant decrease in tumor volume. Mice which were treated with JFL-Ll-TubBH every other day did not show complete response rather a delayed tumor growth was observed.
- mice were treated with same dose of JFL-Ll-TubBH daily, a complete response was observed. Throughout the study weight of the mice were monitored as a measure of gross toxicity. Mice in saline, completion and treatment group that received JFL-Ll-TubBH every other day did not show any decrease in weight. The mice which were treated with the FAP targeted tubulysin displayed an approximately 5 % reduction in weight but the same mice gained the weight towards the end of the treatment.
- mice Female BALB/c mice were injected with 100,000 4T1 cells close to the mammary fat pad. Once the tumor volume reached ⁇ 100 mm the mice were randomly divided into various groups and treatment was initiated. Dosing solutions of FAP targeted tubulysin B hydrazide conjugate (JFL-Ll-TubBH), folate targeted PI3 Kinase inhibitor (FA- PI3K), and folate targeted TLR7 antagonist (FA-TLR7) were prepared in sterile saline and injected intravenously via tail vein.
- JFL-Ll-TubBH folate targeted PI3 Kinase inhibitor
- FA-TLR7 antagonist FAP targeted TLR7 antagonist
- mice in control group were administered with sterile saline whereas mice in treatment group either received the JFL-Ll-TubBH or FA-PI3K or FA- TLR7 alone or in combination with one of the other agents (JFL-Ll-TubBH, FA-PI3K, or FA- TLR7).
- the concentration of single dose used for the treatment were 20 nmoles of JFL-Ll- TubBH, 10 nmoles of FA-PI3K and 10 nmoles of FA-TLR7.
- Mice were injected with the test agents daily followed by tumor volume measurement (caliper). As a measure of gross toxicity, body weight of the mice was also monitored at each dosing.
- Mice in FAP competition group received FAP targeted tubulysin B hydrazide in the presence of excess of the FAP ligand, JFL.
- mice in control and competition (FAP- competition) group did not show any reduction in tumor volume, as shown in Fig. 19A.
- FAP targeted tubulysin B hydrazide JFL-Ll-TubBH
- FA-PI3K folate targeted PI3 Kinase inhibitor
- TLR7 antagonist FA-TLR7
- mice in the other group received FA-PI3K along with JFL-Ll-TubBH.
- both the combination therapy showed a decrease in tumor volume that was additive.
- weight of the mice were monitored as a measure of gross toxicity. None of the group exhibited any weight loss, as shown in Fig. 19B.
- MDA-MB-231 subcutaneous tumor was developed in female NSG mice by injecting 5 million cancer cells. Once the tumor volume reached ⁇ 100 mm the mice were randomized into three different groups and treatment was initiated. Mice in all the groups were administered with 15 million CAR T-cells which has an scFv domain that binds specifically and tightly with fluorescein. 2 h after administration of the CAR T-cells mice in all the groups were given the first dose of the respective test agents.
- mice in the control group were injected with sterile saline whereas mice in treatment arm were either injected with JFL-Ll-FM (10 nmoles) alone or in combination with 100-fold excess of FAP ligand, JFL.
- mice in different groups were administered with the respective test agents intravenously on every other day. As a measure of gross toxicity mice were also weighed at every dosing.
- mice xenograft models were utilized to investigate the effect of CAR T-cell with an scFV domain that recognizes the fluorescein fragment of the FAP targeted FM conjugate (JFL-Ll-FM).
- the mice in control and competition group did not show any difference in the tumor growth rate, as shown in Fig. 20A.
- mice treated with CAR T-cell and FAP targeted FM did not display any reduction in tumor volume. But after 1 week of treatment slight separation in the tumor growth rate was observed. No weight loss was observed in any of the arms of the study, as shown in Fig. 20B.
- the results suggests that FAP targeted CAR T-cell therapy has the potential to kill the tumor but the dose of CAR T-cell and JFL-Ll-FM needs to be optimized to induce tumor suppression earlier in the treatment.
- MDA-MB-231 xenograft was exploited to investigate the in vivo imaging ability of FAP targeted NIR conjugate consisting of PEG and peptidoglycan linker, JFL-L2-S0456, as shown in Figs. 22A-C.
- Whole body imaging revealed that after 2 h post-injection the conjugate was found to be accumulated in the tumor. Biodistribution of vital organs/tissue further confirmed that tumor had the highest uptake of the dye conjugate.
- the other two organs that displayed the uptake of JFL-L2-S0456 were liver and kidneys. The uptake in kidney was higher when compared to the liver. Kidney and liver plays a vital role in excretion of small molecules. The data suggests that the uptake of the FAP targeted dye conjugate in these organs was due to excretion of the fluorescent conjugate via renal and hepatic routes. No uptake was observed in any other organs.
- mice Female athymic mice were implanted with MDA-MB-231 cancer cells to develop subcutaneous tumors. Tumor bearing mice were intravenously injected either with FAP targeted NIR conjugate, JFL-L1-S0456 alone (5 nmoles) or Luteinizing hormone-releasing hormone receptor targeted NIR conjugate, JL-L3-S0456 (5 nmoles) alone or with both the conjugates. 2 h post-injection the mice were euthanized using C0 2 and imaged with Caliper IVIS Lumina II, as shown in Fig. 24A. Followinged by completion of whole body imaging biodistribution was performed and all the organs were imaged to examine the uptake of the dye conjugates, as shown in Fig. 24B.
- HEK-293 cells were seeded in amine coated 24 well plated and allowed to grow as monolayer.
- the spent medium was replaced with medium containing various concentrations of the 99m Tc labeled FAP conjugate (JFL-L3).
- JFL-L3 99m Tc labeled FAP conjugate
- the cells were treated with 99m Tc labeled JFL-L3 in the presence of excess of JFL.
- the apparent K D was determined by analyzing the data using Graph Pad Prism and is shown in Fig. 26.
- FAP targeted conjugate (JFL-L3) for 99m Tc radioactive imaging was synthesized by standard solid phase peptide synthesis.
- the 99m Tc labeled JFL-L3 displayed low nanomolar binding (K D ) of 10.5 nM.
- K D nanomolar binding
- FAP targeted radioactive conjugate was observed to accumulate in the tumor and kidney.
- Other than the tumor and kidney other organs displayed very low to no uptake of the radiolabeled compound.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings relate generally to method of making conjugates comprising a fibroblast activation protein (FAP) inhibitor.
Description
FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND
THERAPY
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional
Application Serial No. 62/434,380, filed December 14, 2016 and U.S. Provisional Application Serial No. 62/575,050, filed October 20, 2017, in which both of which are incorporated herein by reference in their entirety.
TECHNICAL FIELD
[0002] The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient and, in some embodiments, to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings also relate to conjugates and methods for therapeutically treating cancer cells and/or CAFs in a patient.
BACKGROUND
[0003] The tumor microenvironment plays an important role in the growth and development of the tumor. In addition to cancer cells, tumors include infiltrating immune and inflammatory cells such as T cells, tumor associated macrophages, myeloid-suppressor cells, cancer associated fibroblasts (CAF), blood and lymphatic vasculature networks, and
extracellular matrix (ECM). Without the help of these cells, a tumor will fail to acquire immune-escaping, metastatic, and resistance properties.
[0004] CAFs are one of the major type of cells present in the tumor microenvironment and play a role in secretion of many chemokines, cytokines, growth factor, along with modification and degradation of ECM. CAFs overexpress fibroblast activation protein alpha (FAP) which has a limited expression on the healthy cells.
[0005] FAP is a type II membrane integral protein which belongs to a larger family of proteases which are capable of cleaving the proline-amino acid peptide bond. Other members of the same family are dipeptidyl peptidase IV (DPPIV) and proyloligopeptidase (POP). FAP exhibits both endo and exopeptidase activity. FAP is primarily found to be localized on the cell surface but a soluble form of the protein in human plasma has also been reported. FAP exists as a homodimer. FAP is found to be expressed in CAFs of more than 90% of the epithelial solid tumors, tissues involved in wound healing, and remodeling.
[0006] Efficient surgical removal of tumor mass has been improved by fluorescence guided surgery. However, NIR dye conjugates targeted to receptors/proteins overexpressed in cancer cells can image only the antigen positive cancer cells but not the stromal cells. Currently, there is no method available to efficiently image the tumor microenvironment. As such, there is no efficient way of imaging and surgically removing these cells.
SUMMARY
[0007] The scope of the present invention is defined solely by the appended claims, and is not affected to any degree by the statements within this summary.
[0008] Several embodiments of the invention are described in the following enumerated clauses:
[0009] 1. A conjugate, or a pharmaceutically acceptable salt thereof, having a structure
B-L-X,
[0010] wherein B comprises a fibroblast activation protein (FAP) inhibitor;
[0011] L comprises a bivalent linker; and
[0012] X comprises a near infrared (NIR) dye, a radioactive imaging agent, or a therapeutic agent effective against cancer cells and/or cancer-associated fibroblasts (CAF). 0013] 2. The conjugate of clause 1, wherein B has a structure
[0014] wherein R 1 and R 2" are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Q-C4 alkyl;
[0015] R is a Ci-C4 alkyl, nitrile, or isonitrile;
[0016] R4, R5, and R6 are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Q-C4 alkyl; and
[0017] n is an integer from 1 to 8.
[0018] 3. The conjugate of clause 2, or a pharmaceutically acceptable salt thereof, wherein each of R 1 and R 2 is a halogen.
[0019] 4. The conjugate of clause 2 or 3, or a pharmaceutically acceptable salt thereof, wherein each of R 1 and R 2 is fluorine.
[0020] 5. The conjugate of any one of clauses 2 to 4, or a pharmaceutically acceptable salt thereof, wherein R is nitrile.
[0021] 6. The conjugate of any one of clauses 2 to 5, or a pharmaceutically acceptable salt thereof, wherein each of R4, R5, and R6 is hydrogen.
[0022] 7. The conjugate of any one of clauses 2 to 6, or a pharmaceutically acce table salt thereof, wherein B has a structure
[0023] 8. The conjugate of any one of clauses 2 to 7, or a pharmaceutically acceptable salt thereof, wherein B has a structure
[0024] 9. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein the linker comprises at least one amino acid in the D- or reconfiguration, or a derivative thereof, selected from the group consisting of Lys, Asn, Thr, Ser, He, Met, Pro, His, Gin, Arg, Gly, Asp, Glu, Ala, Val, Phe, Leu, Tyr, Cys, and Trp.
[0025] 10. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein the linker comprises at least two amino acids, or a derivative thereof, independently selected from the group consisting of Glu and Cys.
[0026] 11. The conjugate of clause 9 or 10, or a pharmaceutically acceptable salt thereof, wherein the amino acid derivative is a glutamic acid having an amino sugar moiety covalently attached to the side chain carboxylic acid to form an amide bond.
[0027] 12. The conjugate of clause 11, or a pharmaceutically acceptable salt thereof, wherein the amino sugar moiety is 1-deoxy-l-amino-D-glucitol.
[0028] 13. The conjugate of clause 9 or 10, or a pharmaceutically acceptable salt thereof, wherein the linker comprises an amino acid portion of the formula Glu-Glu-Glu, wherein the glutamic acids are optionally substituted with an amino sugar moiety covalently attached to the side chain carboxylic acid to form an amide bond.
[0029] 14. The conjugate of clause 14, or a pharmaceutically acceptable salt thereof, wherein the amino sugar moiety is 1-deoxy-l-amino-D-glucitol.
[0030] 15. The conjugate of clauses 13 or 14, wherein the Glu-Glu-Glu are covalently bonded to each other through the carboxylic acid side chains.
[0031] 16. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein the linker comprises a moiety of the formula
[0032] wherein m is an integer from 0 to 9, p is an integer from 3 to 10, q is an integer from 3 to 100.
[0033] 17. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein the linker comprises a portion selected from the group consisting of
[0034] wherein
[0035] each of R7 and R8 is independently H or C rC6 alkyl;
[0036] t is an integer from 1 to 8.
[0037] 18. The conjugate of clause 17, or a pharmaceutically acceptable salt thereof, wherein the linker is of the formula
[0038] 19. The conjugate of clause 17 or 18, or a pharmaceutically acceptable salt thereof, wherein R 7 and R 8 are H; and t is 2.
[0039] 20. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein the linker comprises a hydrazine
[0040] 21. The conjugate of any one of the preceding clauses, or a pharmaceutically acce table salt thereof, wherein L comprises a structure
[0041] 22. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein the linker comprises a portion selected from the group consistin of
[0042] wherein R6 is H or Ci-C6 alkyl.
[0043] 23. The conjugate of clause 1, or a pharmaceutically acceptable salt thereof, comprising the formula
[0044] 24. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein X comprises a fluorescent dye.
[0045] 25. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein X comprises a NIR dye.
[0046] 26. The conjugate of clause 24, or a pharmaceutically acceptable salt thereof, wherein the fluorescent dye is fluorescein maleimide or fluorescein isothiocyanate (FITC).
[0047] 27. The conjugate of clause 25, or a pharmaceutically acceptable salt thereof, wherein the NIR dye is S0456.
[0048] 28. The conjugate of any one of clauses 1 to 24 or 26, or a pharmaceutically acceptable salt thereof, clause 1 wherein X has a structure
[0049] 29. The conjugate of any one of clauses 1 to 23 or 25, or a pharmaceutically acceptable salt thereof, wherein X has a structure
[0050] The conjugate of clause 1 having a structure
[0051] pharmaceutically acceptable salt thereof.
[0052] The conjugate of clause 1 having a structure
[0054] 32. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X is a chelating agent of the formula
[0055] 33. The conjugate of clause 32, or a pharmaceutically acceptable salt thereof, wherein X comprises a radioactive metal isotope coordinated to the chelating agent.
[0056] A conjugate having a structure
[0057] wherein L comprises a bivalent linker; and
[0058] X comprises a near infrared (NIR) dye.
[0059] 35. The conjugate of clause 34 having a structure
[0060] 36. A method of surgically removing cancer-associated fibroblasts (CAFs) from a patient, the method comprising:
[0061] delivering a conjugate to a tumor microenvironment of the patient, the tumor microenvironment comprising at least one CAF, the conjugate having a structure
[0062] wherein L comprises a bivalent linker and X comprises a near infrared (NIR) dye;
[0063] causing the NIR dye to fluoresce through an application of an optical stimulus thereto; and
[0064] cutting CAF-containing tissue of the patient based on a result of the
fluorescence.
[0065] 37. The method of clause 22 wherein the CAF-containing tissue imaged by the conjugate comprises stromal cells.
[0066] 38. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein A is a drug selected from the group consisting of a vinca alkaloid, a cryptophycin, bortezomib, thiobortezomib, a tubulysin, aminopterin, rapamycin, paclitaxel, docetaxel, doxorubicin, daunorubicin, everolimus, a-amanatin, verucarin, didemnin B, geldanomycin, purvalanol A, ispinesib, budesonide, dasatinib, an epothilone, a maytansine, and a tyrosine kinase inhibitor.
[0067] 39. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the drug is a tubulysin.
[0068] 40. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the drug is a tetrapeptide of the formula
[0069] wherein
[0070] Rla, R3a, R3a and R3a are each independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each hyd:
atom in Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently optionally substituted by halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, 5- to 7-membered heteroaryl, -OR13a, - OC(0)R13a, -OC(0)NR13aR13a', -OS(0)R13a, -OS(0)2R13a, -SR13a, -SC(0)R13a, -S(0)R13a, - S(0)2R13a, -S(0)2OR13a, -S(0)NR13aR13a', -S(0)2NR13aR13a', -OS(0)NR13aR13a',
-OS(0)2NR13aR13a', -NR13aR13a', -NR13aC(0)R14a, -NR13aC(0)OR14a, -NR13aC(0)NR14aR14a', -NR13aS(0)R14a, -NR13aS(0)2R14a, -NR13aS(0)NR13aR14a', -NR13aS(0)2NR14aR14a',
-P(0)(OR13a)2, -C(0)R13a, -C(0)OR13a or -C(0)NR13aR13a';
[0071] R2a, R4a and R12a are each independently selected from the group consisting of H,
Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl;
[0072] R5a and R6a are each independently selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR15a, -SR15a and -NR15aR15a', wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl and C2_C6 alkynyl is independently optionally substituted by halogen, -OR16a, -SR16a, -NR16aR16a', -C(0)R16a, -C(0)OR16a or -C(0)NR16aR16a ; or R5a and R6a taken together with the carbon atom to which they are attached form a -C(O)-;
[0073] each R7a, R8a, R9a, R10a and Rlla is independently selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -CN, -N02, -NCO, -OR17a, -SR17a, -S(0)2OR17a, -NR17aR17a', -P(0)(OR17a)2, -C(0)R17a, -C(0)OR17a and -C(0)NR17aR17a', wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl is independently optionally substituted by halogen, -OR18a, -SR18a, -NR18aR18a', -C(0)R18a, -C(0)OR18a or -C(0)NR18aR18a';
[0074] each R13a, R13a', R14a, R14a', R15a, R15a', R16a, R16a', R17a and R17a' is independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in Ci-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH, -NH2 or -C02H;
[0075] each R 18a and R 18a' is independently selected from the group consisting of H, C\-
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-Cio aryl, 5- to 7-membered heteroaryl -C(0)R19a, -P(0)(OR19a)2, and -S(0)2OR19a,
[0076] each R19a is independently selected from H, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7- membered heteroaryl; and
0077] a is 1, 2 or 3.
[0079] wherein
[0080] Rla, R3a, R3a and R3a are each independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and C3_C6 cycloalkyl is independently optionally substituted by halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2 C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, 5- to 7-membered heteroaryl, -OR13a, - OC(0)R13a, -OC(0)NR13aR13a', -OS(0)R13a, -OS(0)2R13a, -SR13a, -SC(0)R13a, -S(0)R13a, - S(0)2R13a, -S(0)2OR13a, -S(0)NR13aR13a', -S(0)2NR13aR13a', -OS(0)NR13aR13a',
-OS(0)2NR13aR13a', -NR13aR13a', -NR13aC(0)R14a, -NR13aC(0)OR14a, -NR13aC(0)NR14aR14a', -NR13aS(0)R14a, -NR13aS(0)2R14a, -NR13aS(0)NR13aR14a', -NR13aS(0)2NR14aR14a',
-P(0)(OR13a)2, -C(0)R13a, -C(0)OR13a or -C(0)NR13aR13a';
[0081] R2a, R4a and R12a are each independently selected from the group consisting of H,
Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl;
[0082] R5a is selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR15a, -SR15a and -NR15aR15a', wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl is independently optionally substituted by halogen, - OR16a, -SR16a, -NR16aR16a', -C(0)R16a, -C(0)OR16a or -C(0)NR16aR16a';
[0083] each R7a, R8a, R9a, R10a and Rlla is independently selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CN, -N02, -NCO, -OR17a, -SR17a, -S(0)2OR17a, -NR17aR17a', -P(0)(OR17a)2, -C(0)R17a, -C(0)OR17a and -C(0)NR17aR17a', wherein each hydrogen atom in Q-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl is independently optionally substituted by halogen, -OR18a, -SR18a, -NR18aR18a', -C(0)R18a, -C(0)OR18a or -C(0)NR18aR18a';
[0084] each R13a, R13a', R14a, R14a', R15a, R15a', R16a, R16a', R17a and R17a' is independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in Q-G7 alkyl, C2-C7 alkenyl, C2-C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH, -N¾ or -CO2H;
18a 18a'
[0085] each R and R is independently selected from the group consisting of H, C\-
C alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-Cio aryl, 5- to 7-membered heteroaryl -C(0)R19a, -P(0)(OR19a)2, and -S(0)2OR19a,
[0086] each R19a is independently selected from H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7- membered heteroaryl; and
[0087] a is 1, 2 or 3.
[0088] 42. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein D is a tetra eptide of the formula
[0089] wherein
[0090] R9a is selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CN, -N02, -NCO, -OR17a, -SR17a, -S(0)2OR17a, -NR17aR17a', - P(0)(OR17a)2, -C(0)R17a, -C(0)OR17a and -C(0)NR17aR17a', wherein each hydrogen atom in d- C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl is independently optionally substituted by halogen, - OR18a, -SR18a, -NR18aR18a', -C(0)R18a, -C(0)OR18a or -C(0)NR18aR18a';
[0091] each R13a, R17a and R17a is independently selected from the group consisting of
H, CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C7 alkyl, C2-C7 alkenyl, C2-C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH, -NH2 or -C02H;
18a 18a'
[0092] each R and R is independently selected from the group consisting of H, Ci-
C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-Cio aryl, 5- to 7-membered heteroaryl -C(0)R19a, -P(0)(OR19a)2, and -S(0)2OR19a,
[0093] each R19a is independently selected from H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7-
membered heteroaryl.
[0094] 43. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein A is a naturally occurring tubulysin.
[0095] 44. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of tubulysin A, tubulysin B, tubulysin C, tubulysin D, tubulysin E, tubulysin F, tubulysin G, tubulysin H and tubulysin I.
[0096] 45. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the drug is tubulysin B.
[0097] 46. The conjugate of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein A is of the formula
[0098] 47. The conjugate of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein A is of the formula
[0099 48. A conjugate of the formula
[00100] or a pharmaceutically acceptable salt thereof.
[00101] 49. The conjugate of clause 48, or a pharmaceutically acceptable salt thereof, wherein the conjugate comprises a radioactive metal isotope selected from the group consisting of mIn, 99mTc, ^Cu, 67Cu, 67Ga and 68Ga coordinated thereto.
[00102] 50. The conjugate of clause 49, wherein the radioactive metal isotope is
99mTc.
[00103] 51. A conjugate of the formula
[00104] or a pharmaceutically acceptable salt thereof.
[00105] 52. A conjugate of the formula
[00106] 53. A pharmaceutical composition comprising a conjugate of any of the preceding clauses, or a pharmaceutically acceptable salt thereof, and optionally at least one pharmaceutically acceptable excipient.
[00107] 54. A method of treating cancer in a subject, comprising,
[00108] a. administering to the subject an effective amount of a conjugate or composition according to any one of clauses 1 to 23, 38 to 47 or 51; or a pharmaceutically acceptable salt thereof.
[00109] 55. The method of clause 54, wherein the subject has a FAP expressing cancer.
[00110] 56. The method of clause 54 or 55, wherein FAP expressing cancer is primary or metastatic.
[00111] 57. The method of any one of clauses 44 to 56, wherein the cancer is selected from the group consisting of prostate, endometrial, skin, pancreatic, breast, kidney, ovarian and brain cancer.
[00112] 58. A conjugate according to any one of clause 1 to 23, 38 to 47 or 51, or a pharmaceutically acceptable salt thereof, for use in a method of treating FAP expressing cancer in a subject.
[00113] 59. The conjugate of clause 58, wherein the method comprises administering to the subject an amount of the conjugate effective for treating the FAP expressing cancer.
[00114] 60. The conjugate of clause 58 or 59, wherein the FAP expressing cancer is selected from the group consisting of prostate, endometrial, skin, pancreatic, breast, kidney, ovarian and brain cancer.
[00115] 61. Use of a conjugate according to any one of clauses 1 to 23, 38 to 47 or 51, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament useful for treating FAP expressing cancer in a subject.
[00116] 62. The use of clause 61, wherein the FAP expressing cancer is selected from the group consisting of prostate, endometrial, skin, pancreatic, breast, kidney, ovarian and brain cancer.
[00117] 63. A method of imaging a population of cells in vitro, comprising
[00118] a. contacting the cells with a conjugate according to any one of clauses 1 to 31, to provide labelled cells, and
[00119] b. visualizing the labelled cells.
[00120] 64. A conjugate according to any one of clauses 1 to 31, for use in a method of imaging a population of cells in vitro.
[00121] 65. The conjugate of clause 63, wherein the method comprises
[00122] a. contacting the cells with a conjugate according to any one of clauses 1 to 31, to provide labelled cells, and
[00123] b. visualizing the labelled cells.
[00124] 66. A method of imaging a population of cells in vivo, comprising
[00125] a. administering to a patient an effective amount of a conjugate according to any one of clauses 1 to 23, 32, 33, 48 or 49, or a pharmaceutically acceptable salt thereof, to provide labelled cells; and
[00126] b. visualizing the labelled cells by imaging.
[00127] 67. A conjugate according to any one of clauses 1 to 23, 32, 33, 48 or 49, for use in a method of imaging a population of cells in vitro.
[00128] 68. The conjugate of clause 67, wherein the method comprises
[00129] a. administering to a patient an effective amount of a conjugate according to any one of clauses 1 to 23, 32, 33, 48 or 49, or a pharmaceutically acceptable salt thereof, to provide labelled cells; and
[00130] b. visualizing the labelled cells by imaging.
BRIEF DESCRIPTION OF THE DRAWINGS
[00131] FIG. 1 shows the chemical structure and an LC/MS trace for Compound 3.
[00132] FIG. 2 shows the chemical structure and an LC/MS trace for Compound 4.
[00133] FIG. 3 shows the chemical structure and an LC/MS trace for Compound 5.
[00134] FIG. 4 shows the chemical structure and an LC/MS trace for Compound 7.
[00135] FIG. 5 shows the chemical structure and an LC/MS trace for Compound 8 (JFL).
[00136] FIG. 6 shows the chemical structure and an LC/MS trace for Compound 10.
[00137] FIG. 7 shows the chemical structure and an LC/MS trace for JFL-L1.
[00138] FIG. 8 shows the chemical structure and an LC/MS trace for JFL-L1-FM.
[00139] FIG. 9 shows the chemical structure and an LC/MS trace for S0456 maleimide.
[00140] FIG. 10 shows the chemical structure and an LC/MS trace for JFL-L1-S0456.
[00141] Figure 11 shows in vitro confocal imaging results with JFL-L1-FM.
[00142] Figure 12 shows in vitro binding affinity of JFL-L1-S0456FAP transfected HEK293 cells as determined by fluorescence vs. concentration.
[00143] Figure 13 shows in vivo imaging of JFL-L1-S0456 in FaDu mouse xenografts.
[00144] Figure 14 shows in vivo imaging of JFL-L1-S0456 in KB mouse xenografts.
[00145] Figure 15 shows in vivo imaging of JFL-L1-S0456 in HT29 mouse xenografts.
[00146] Figure 16 shows in vivo imaging of JFL-L1-S0456 in MDA-MB231 mouse xenografts.
[00147] Figure 17 shows the LC/MS trace for JFL-Ll-TubBH.
[00148] Figure 18A shows tumor volume over time in response to treatment with JFL-Ll- TubBH and Figure 18B shows body weight of the mice used in the experiment. (A) Control; (♦) FAP-competition; (-) Consecutive days - FAP-TubBH (40 nmoles); (·) daily FAP-TubBH (40 nmoles).
[00149] Figure 19A shows tumor volume over time in response to JFL-Ll-TubBH and JFL-Ll-TubBH in combination with other treatments, and Figure 19B shows the body weight of the mice used in the experiment. (Δ) Control; (A) FAP-competition; (■) FAP-TubBH; (T ) Folate-TLR7; (·) Folate-PI3K; (□) FAP-TubBH & Folate-TLR7; (o) FAP-TubBH & Folate- PI3K.
[00150] Figure 20A shows tumor volume over tie in response to JFL-L1-FM and Figure 20B shows the body weight of the mice used in the experiment, (o) Control; (■) FAP-FM; (·) FAP-competition.
[00151] Figure 21A-B shows the LC/MS trace for JFL-L2-S0456.
[00152] Figures 22A-C show in vivo imaging with JFL-L2-S0456.
[00153] Figure 23 shows in vivo imaging using different concentrations of JFL-L1-S0456.
[00154] Figures 24A-B show Cocktail Imaging: FAPa and LHRH-R targeted NIR conjugates.
[00155] Figures 25A-B show the LC/MS traces for JFL-L3.
[00156] Figure 26 shows in vitro binding affinity of JFL-L3.
[00157] Figures 27A-C show in vivo imaging of JFL-L3
DETAILED DESCRIPTION
[00158] Several embodiments of the invention are described by the following enumerated clauses and any combination of these embodiments with the embodiments described in this Detailed Description section is contemplated. It is to be understood that elements and features of the various representative embodiments described below may be combined in different ways to produce new embodiments that likewise fall within the scope of the present teachings.
[00159] 1. A conjugate having a structure
B-L-X,
wherein B comprises a fibroblast activation protein (FAP) inhibitor; L comprises a bivalent linker; and X comprises a near infrared (NIR) dye, a radioactive imaging agent, or a therapeutic agent effective against cancer cells and/or cancer- associated fibroblasts (CAF).
[00160] 2. The conjugate of clause 1 wherein B has a structure
wherein R 1 and R 2 are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Ci-C4 alkyl; R is a Ci-C4 alkyl, nitrile, or isonitrile; and R4, R5, and R6 are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Ci-C4 alkyl.
[00161] 3. The conjugate of any preceding clause wherein each of R 1 and R 2 is a halogen.
[00162] 4. The conjugate of any preceding clause wherein each of R 1 and R 2 is fluorine.
[00163] 5. The conjugate of any preceding clause wherein R is nitrile.
[00164] 6. The conjugate of any preceding clause wherein each of R4, R5, and R6 is hydrogen.
[00165] 7. The conjugate of any preceding clause wherein B has a structure
[00166] 8. The con ugate of any preceding clause wherein B has a structure
[00167] 9. The conjugate of any preceding clause wherein L comprises a structure
[00168] 10. The conjugate of any preceding clause wherein L comprises a structure
[00169] 11. The conjugate of any preceding clause wherein X comprises a NIR dye.
[00170] 12. The conjugate of any preceding clause wherein the NIR dye is fluorescein isothiocyanate (FITC).
[00171] 13. The conjugate of any preceding clause wherein the NIR dye is S0456.
[00172] 14. The conjugate of any preceding clause wherein X has a structure
[00173] 15. The conjugate of any preceding clause wherein X has a structure
[00175] 17. The conjugate of any preceding clause having a structure
[00176] 18. The conjugate of any one of clauses 1-10 wherein X comprises a radioactive imaging agent.
[00177] 19. The conjugate of any one of clauses 1-10 wherein X comprises a therapeutic agent effective against cancer cells and/or CAFs.
wherein L comprises a bivalent linker; and X comprises a near infrared (NIR)
[00179] 21. The conjugate of clause 20 having a structure
[00180] 22. A method of surgically removing cancer-associated fibroblasts (CAFs) from a patient, the method comprising:
delivering a conjugate to a tumor microenvironment of the patient, the tumor microenvironment com rising at least one CAF, the conjugate having a structure
wherein L comprises a bivalent linker and X comprises a near infrared (NIR) dye; causing the NIR dye to fluoresce through an application of an optical stimulus thereto; and cutting CAF-containing tissue of the patient based on a result of the fluorescence.
[00181] 23. The method of clause 22 wherein the CAF-containing tissue imaged by the conjugate comprises stromal cells.
[00182] In each of the foregoing and each of the following embodiments, it is to be understood that the formulae include and represent not only all pharmaceutically acceptable
salts of the conjugates, but also include any and all hydrates and/or solvates of the conjugate formulae. It is appreciated that certain functional groups, such as the hydroxy, amino, and like groups form complexes and/or coordination conjugates with water and/or various solvents, in the various physical forms of the conjugates. Accordingly, the above formulae are to be understood to include and represent those various hydrates and/or solvates. It is also to be understood that the non-hydrates and/or non-solvates of the conjugate formulae are described by such formula, as well as the hydrates and/or solvates of the conjugate formulae.
[00183] Throughout this description and in the appended claims, the following definitions are to be understood:
[00184] As used herein, the phrase "Ci-C4 alkyl" refers to a straight, branched or cyclic hydrocarbon chain containing from 1 to 4 carbon atoms. Representative examples of Ci-C4 alkyl groups in accordance with the present teachings include but are not limited to methyl, ethyl, propyl, z'so-propyl, cyclopropyl, butyl, z'so-butyl, ieri-butyl, sec-butyl, and cyclobutyl.
[00185] As used herein, the term "halogen" refers to fluorine, chlorine, iodine or bromine.
[00186] As used herein, "amino acid" (a.k.a. "AA") means any molecule that includes an alpha-carbon atom covalently bonded to an amino group and an acid group. The acid group may include a carboxyl group. "Amino acid" may include molecules having one of the formulas:
[00187] or a derivative thereof, wherein R' is a side group and Φ includes at least 3 carbon atoms. "Amino acid" includes stereoisomers such as the D-amino acid and L-amino acid forms. Illustrative amino acid groups include, but are not limited to, the twenty endogenous human amino acids and their derivatives, such as lysine (Lys), asparagine (Asn), threonine (Thr), serine (Ser), isoleucine (He), methionine (Met), proline (Pro), histidine (His), glutamine (Gin), arginine (Arg), glycine (Gly), aspartic acid (Asp), glutamic acid (Glu), alanine (Ala), valine (Val), phenylalanine (Phe), leucine (Leu), tyrosine (Tyr), cysteine (Cys), tryptophan (Trp), phosphoserine (PSER), sulfo-cysteine, arginosuccinic acid (ASA), hydroxyproline, phosphoethanolamine (PEA), sarcosine (SARC), taurine (TAU), camosine (CARN), citrulline (CIT), anserine (ANS), 1,3-methyl-histidine (ME-HIS), alpha-amino-adipic acid (AAA), beta- alanine (BALA), ethanolamine (ETN), gamma-amino-butyric acid (GABA), beta-amino- isobutyric acid (BAIA), alpha-amino-butyric acid (BABA), L-allo-cystathionine (cystathionine- A; CYSTA-A), L-cystathionine (cystathionine-B; CYSTA-B), cystine, allo-isoleucine (ALLO-
ILE), DL-hydroxylysine (hydroxylysine (I)), DL-allo-hydroxylysine (hydroxylysine (2)), ornithine (ORN), homocystine (HCY), and derivatives thereof. In connection with the embodiments described herein, amino acids can be covalently attached to other portions of the conjugates described herein through their alpha-amino and carboxy functional groups (i.e. in a peptide bond configuration), or through their side chain functional groups (such as the side chain carboxy group in glutamic acid) and either their alpha-amino or carboxy functional groups. It will be understood that amino acids, when used in connection with the conjugates described herein, may exist as zwitterions in a conjugate in which they are incorporated.
[00188] In some embodiments, a derivative of an amino acid includes an amino acid that includes a substituent on the side-chain that is not present on a natural amino acid. Some examples of derivatives are provided above. In some embodiments, a derivative of glutamic acids includes the covalent attachment of an amine substituent through the carboxylic acid on the glutamic acid side-chain to form an amide bond. In some embodiments, the amine substituent is an amino sugar, such as 1-deoxy-l-amino-D-glucitol as shown below.
[00189] As used herein, the phrase "therapeutically effective amount" refers to an amount of a drug or pharmaceutical agent that elicits the biological or medicinal response in a subject (i.e. a tissue system, animal or human) that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes, but is not limited to, alleviation of the symptoms of the disease or disorder being treated. In one aspect, the therapeutically effective amount is that amount of an active which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment. In another aspect, the therapeutically effective amount is that amount of an inactive prodrug which when converted through normal metabolic processes to produce an amount of active drug capable of eliciting the biological or medicinal response in a subject that is being sought.
[00190] It is also appreciated that the dose, whether referring to monotherapy or combination therapy, is advantageously selected with reference to any toxicity, or other undesirable side effect, that might occur during administration of one or more of the conjugates described herein. Further, it is appreciated that the co-therapies described herein may allow for
the administration of lower doses of conjugates that show such toxicity, or other undesirable side effect, where those lower doses are below thresholds of toxicity or lower in the therapeutic window than would otherwise be administered in the absence of a cotherapy.
[00191] As used herein, the term "administering" includes all means of introducing the conjugates and compositions described herein to the host animal, including, but are not limited to, oral (po), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, inhalation, buccal, ocular, sublingual, vaginal, rectal, and the like. The conjugates and compositions described herein may be administered in unit dosage forms and/or formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants, and/or vehicles.
[00192] As used herein, the phrase "pharmaceutical composition" or "composition" refers to a mixture of one or more of the conjugates in accordance with the present teachings, or pharmaceutically acceptable salts, solvates, hydrates thereof, with other chemical components, such as pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of a conjugate to a subject. Pharmaceutical compositions suitable for the delivery of conjugates in accordance with the present teachings and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
[00193] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein may be used in the practice or testing of the present teachings, the preferred methods, devices and materials are now described.
[00194] In some embodiments, a conjugate in accordance with the present teachings includes an imaging agent, such as a near infrared (NIR) dye or a radioactive imaging agent. Representative compounds that may be used as imaging agents in accordance with the present teachings include but are not limited to dyes {e.g., rhodamine dyes, cyanine dyes, fluorescein dyes, etc.), PET imaging agents, radiolabeled agents, and the like. Representative examples of rhodamine dyes include but are not limited to 5-carboxytetramethylrhodamine (5-TAMRA), rhodamine B, rhodamine 6G, TRITC, Texas Red, rhodamine 123, sulforhodamine 101, and the like. Examples of fluorescein dyes include but are not limited to fluorescein, fluorescein maleimide (FM), 5 -amino-fluorescein, 6-amino-fluorescein, fluorescein isocyanate (FITC), NHS -fluorescein, Oregon Green, Tokyo Green, Singapore Green, Philadelphia Green, and the like. Representative near infrared dyes that may be used in accordance with the present
teachings include but are not limited to LS288, IR800, SP054, S0121, KODAK, IRD28, S2076, S0456, and derivatives thereof.
[00195] In some embodiments, a radiolabeled agent may be used as an imaging agent in accordance with the present teachings. In some embodiments, a rhodamine dye or fluorescein dye may be isotopically labelled. Examples of isotopes suitable for inclusion in the conjugates include isotopes of hydrogen (e.g., 2 H and 3 H), carbon (e.g., 11 C, 13 C, and 14 C), chlorine (e.g., 36C1), fluorine (e.g., 18F), iodine (e.g., 123I and 125I), nitrogen (e.g., 13N and 15N), oxygen (e.g., 150, 170, and 180), phosphorus (e.g., 32P), and sulfur (e.g., 35S).
[00196] Certain isotopically-labelled conjugates, for example, those incorporating a radioactive isotope, may be useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium (i.e., 3 H), and carbon- 14 (i.e., 14 C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
[00197] Substitution with positron emitting isotopes, such as 11 C, 18 F, and 13 N, may be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled conjugates may generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagents in place of the non- labeled reagent previously employed.
[00198] In some embodiments, the present disclosure provides methods for imaging a population of cell or tissue, either in vitro or in vivo. It will be appreciated that such in vitro methods may be carried out by any method known in the art. In some embodiments, in vitro imaging methods described herein may include (a) contacting a population of cells with a conjugate in accordance with the present teachings that is suitable for imaging to provide the conjugate bound to cells expressing a FAP protein, and (b) visualizing the conjugate bound to cells by irradiation with light. It will be appreciated that visualizing the conjugate bound to cells by irradiation with light may include irradiation at an excitation wavelength and detection at an emission wavelength. Thus, in some embodiments, in vitro imaging methods described herein may include (a) contacting a population of cells with a conjugate in accordance with the present teachings that is suitable for imaging to provide the conjugate bound to cells expressing a FAP protein, (b) irradiating the conjugate bound to cells expressing a FAP protein with an excitation wavelength light, and (c) detecting light emitted from the cancer cells at an emission wavelength.
[00199] In some embodiments, tissues, such as cancerous tumors, may be imaged according to the methods described herein. For example, in some embodiments, in vivo
imaging methods in accordance with the present teachings may include (a) administering to the patient a conjugate in accordance with the present teachings that is suitable for imaging; or a pharmaceutically acceptable salt thereof, to provide the conjugate bound to cells expressing a FAP protein; and (b) visualizing the conjugate bound to cells expressing a FAP protein by irradiation with light. It will be appreciated that visualizing the conjugate bound to cells by irradiation with light may include irradiation at an excitation wavelength and detection at an emission wavelength. Thus, in some embodiments, in vivo imaging methods described herein may include (a) administering to the patient a conjugate as described herein that is suitable for imaging; or a pharmaceutically acceptable salt thereof, to provide the conjugate bound to cells expressing a FAP protein; (b) irradiating the conjugate bound to cells expressing a FAP protein with an excitation wavelength light; and (c) detecting light emitted from the cancer cells at an emission wavelength. It will be appreciated that visualizing the conjugate bound to cells by irradiation with light may be carried out using any known imaging techniques (diagnostic or otherwise) or instrumentation known in the art.
[00200] In some embodiments, a conjugate in accordance with the present teachings includes a therapeutic agent which, in some embodiments, is therapeutically effective against cancer cells and/or cancer-associated fibroblast (CAFs). The therapeutic agent used in accordance with the present teachings may be any molecule capable of modulating or otherwise modifying cell function, including pharmaceutically active compounds (e.g. , a therapeutic agent), or any molecule capable of providing a measurable signal for imaging or visualized cells or tissues (e.g. , an imaging agent).
[00201] Suitable molecules that may be useful as therapeutic agents include but are not limited to peptides, oligopeptides, retro-inverso oligopeptides, proteins, protein analogs in which at least one non-peptide linkage replaces a peptide linkage, apoproteins, glycoproteins, enzymes, coenzymes, enzyme inhibitors, amino acids and their derivatives, receptors and other membrane proteins; antigens and antibodies thereto; haptens and antibodies thereto; hormones, lipids, phospholipids, liposomes; toxins; antibiotics; analgesics; bronchodilators; beta-blockers; antimicrobial agents; antihypertensive agents; cardiovascular agents including antiarrhythmics, cardiac glycosides, antianginals and vasodilators; central nervous system agents including stimulants, psychotropics, antimanics, and depressants; antiviral agents; antihistamines; cancer drugs including chemotherapeutic agents; tranquilizers; anti-depressants; H-2 antagonists; anticonvulsants; antinauseants; prostaglandins and prostaglandin analogs; muscle relaxants; anti-inflammatory substances; stimulants; decongestants; antiemetics; diuretics;
antispasmodics; antiasthmatics; anti-Parkinson agents; expectorants; cough suppressants;
mucolytics; and mineral and nutritional additives.
[00202] In some embodiments, the therapeutic agent may be a tubulysin. Natural tubulysins are generally linear tetrapeptides consisting of N-methyl pipecolic acid (Mep), isoleucine (He), an unnatural aminoacid called tubuvaline (Tuv), and either an unnatural aminoacid called tubutyrosine (Tut, an analog of tyrosine) or an unnatural aminoacid called tubuphenylalanine (Tup, an analog of phenylalanine).
[00203] In some embodiments the therapeutic agent is a tetrapeptide of the formula
[00204] wherein Rla, R3a, R3a and R3a are each independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and C3-C6 cycloalkyl is
independently optionally substituted by halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3_ C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, 5- to 7-membered heteroaryl, - OR13a, -OC(0)R13a, -OC(0)NR13aR13a', -OS(0)R13a, -OS(0)2R13a, -SR13a, -SC(0)R13a, - S(0)R13a, -S(0)2R13a, -S(0)2OR13a, -S(0)NR13aR13a', -S(0)2NR13aR13a', -OS(0)NR13aR13a', -OS(0)2NR13aR13a', -NR13aR13a', -NR13aC(0)R14a, -NR13aC(0)OR14a, -NR13aC(0)NR14aR14a', -NR13aS(0)R14a, -NR13aS(0)2R14a, -NR13aS(0)NR13aR14a', -NR13aS(0)2NR14aR14a', - P(0)(OR13a)2, -C(0)R13a, -C(0)OR13a or -C(0)NR13aR13a';
[00205] R2a, R4a and R12a are each independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl;
[00206] R5a and R6a are each independently selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -OR15a, -SR15a and -NR15aR15a', wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl and C2 C6 alkynyl is independently optionally substituted by halogen, -OR16a, -SR16a, -NR16aR16a', -C(0)R16a, -C(0)OR16a or -C(0)NR16aR16a ; or R5a and R6a taken together with the carbon atom to which they are attached form a -C(O)-;
[00207] each R7a, R8a, R9a, R10a and Rlla is independently selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CN, -N02, -NCO, -OR17a,
-SR17a, -S(0)2OR17a, -NR17aR17a', -P(0)(OR17a)2, -C(0)R17a, -C(0)OR17a and -C(0)NR17aR17a', wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl is independently optionally substituted by halogen, -OR18a, -SR18a, -NR18aR18a', -C(0)R18a, -C(0)OR18a or -C(0)NR18aR18a';
[00208] each R13a, R13a', R14a, R14a', R15a, R15a', R16a, R16a', R17a and R17a' is independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C7 alkyl, C2-C7 alkenyl, C2-C7 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH, -NH2 or -C02H;
[00209] each 18a 18a'
R and R is independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6- C10 aryl, 5- to 7-membered heteroaryl -C(0)R19a, -P(0)(OR19a)2, and -S(0)2OR19a,
[00210] each R19 is independently selected from H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7- membered heteroaryl;
[00211] a is 1, 2 or 3; and
[00212] * represents a covalent bond to the rest of the conjugate.
[00213] In some embodiments, the therapeutic agent is of the formula
[00214] wherein Rla, R2a, R3a, R3a', R3a",R4a, R5a, R7a, R8a, R9a, R10a, Rl la and R12a are as described herein, and * represents a covalent bond to the rest of the conjugate.
[00215] In another embodiment, the therapeutic agent may be a naturally occurring tubulysin, or analog or derivative thereof, of the following general formula
[00216] wherein R a and R a are as described herein, and * represents a covalent bond to the rest of the conjugate.
[00217] Conjugates of each of the foregoing tubulysins are described herein.
[00218] In some embodiments, the therapeutic agent may be a naturally occurring tubulysin of the following general formula
[00219] and * represents a covalent bond to the rest of the conjugate
[00220] In some embodiments, the methods in accordance with the present teachings may be used for both human clinical medicine and veterinary applications as a "subject". Thus, a "subject" may be administered the conjugates in accordance with the present teachings, and may be human ("patient") or, in the case of veterinary applications, may be a laboratory, agricultural, domestic, or wild animal. In some embodiments, the subject may be a human patient, a laboratory animal such as a rodent (e.g. , mice, rats, hamsters, etc.), a rabbit, a monkey, a chimpanzee, domestic animals such as dogs, cats, and rabbits, agricultural animals such as cows, horses, pigs, sheep, goats, and wild animals in captivity such as bears, pandas, lions, tigers, leopards, elephants, zebras, giraffes, gorillas, dolphins, and whales.
[00221] In some embodiments, the cancers described herein may be a cancer cell population that is tumorigenic, including benign tumors and malignant tumors, or the cancer may be non-tumorigenic. The cancer may arise spontaneously or by such processes as mutations present in the germline of the patient or somatic mutations, or the cancer may be chemically-, virally-, or radiation-induced. Cancers applicable to the present teachings include but are not limited to a carcinoma, a sarcoma, a lymphoma, a melanoma, a mesothelioma, a nasopharyngeal carcinoma, a leukemia, an adenocarcinoma, and a myeloma.
[00222] In some embodiments, the cancers may be lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head, cancer of the neck, cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer, endometrial cancer, leiomyosarcoma, rectal cancer, stomach cancer, colon cancer, breast cancer, triple negative breast cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, non-small cell lung cancer, small cell lung cancer, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic leukemia, acute leukemia, lymphocytic lymphomas, pleural mesothelioma, cancer of the bladder, Burkitt's lymphoma, cancer of the ureter, cancer of the kidney, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma,
cholangiocarcinoma, Hurthle cell thyroid cancer or adenocarcinoma of the gastroesophageal junction.
[00223] In some embodiments of the methods described herein, pharmaceutically acceptable salts of conjugates in accordance with the present teachings are provided.
Pharmaceutically acceptable salts of conjugates in accordance with the present teachings include acid addition and base salts thereof.
[00224] Suitable acid addition salts are formed from acids which form non-toxic salts. Illustrative examples include but are not limited to the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts.
[00225] Suitable base salts of the conjugates described herein are formed from bases which form non-toxic salts. Illustrative examples include but are not limited to the arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
[00226] In some embodiments, conjugates in accordance with the present teachings may be administered as a formulation in association with one or more pharmaceutically acceptable
carriers. The carriers may be excipients. The choice of carrier may depend on factors such as the particular mode of administration, the effect of the carrier on solubility and stability, and the nature of the dosage form. Pharmaceutical compositions suitable for the delivery of conjugates as described herein and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington: The Science & Practice of Pharmacy, 21th Edition (Lippincott Williams &
Wilkins, 2005).
[00227] In some embodiments, a pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, and combinations thereof, that are physiologically compatible. In some embodiments, the carrier is suitable for parenteral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Supplementary active compounds may also be incorporated into compositions of the invention.
[00228] In some embodiments, liquid formulations may include suspensions and solutions. Such formulations may comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid.
[00229] In some embodiments, an aqueous suspension may contain the active materials in admixture with appropriate excipients. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally-occurring phosphatide, for example, lecithin; a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example,
heptadecaethyleneoxycetanol; a condensation product of ethylene oxide with a partial ester derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate; or a condensation product of ethylene oxide with a partial ester derived from fatty acids and hexitol anhydrides, for example, polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example, ascorbic acid, ethyl, n-propyl, or p- hydroxybenzoate; or one or more coloring agents.
[00230] In some embodiments, dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture
with a dispersing or wetting agent, suspending agent and one or more preservatives. Additional excipients, for example, coloring agents, may also be present.
[00231] Suitable emulsifying agents may be naturally-occurring gums, for example, gum acacia or gum tragacanth; naturally-occurring phosphatides, for example, soybean lecithin; and esters including partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan mono-oleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
[00232] In some embodiments, isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride may be included in the composition. Prolonged absorption of injectable compositions may be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin.
[00233] Illustrative formats for oral administration include but are not limited to tablets, capsules, elixirs, syrups, and the like.
[00234] Depending upon the cancer type as described herein, the route of administration and/or whether the conjugates are administered locally or systemically, a wide range of permissible dosages are contemplated herein, including doses falling in the range from about 1 μg/kg to about 1 g/kg. The dosages may be single or divided, and may administered according to a wide variety of protocols, including q.d., b.i.d., t.i.d., or even every other day, biweekly (b.i.w.), once a week, once a month, once a quarter, and the like. In each of these cases it is understood that the therapeutically effective amounts described herein correspond to the instance of administration, or alternatively to the total daily, weekly, month, or quarterly dose, as determined by the dosing protocol.
[00235] In some embodiments, a conjugate in accordance with the present teachings may be administered directly into the blood stream, into muscle, or into an internal organ. Suitable routes for such parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, epidural, intracerebroventricular, intraurethral, intrasternal, intracranial,
intratumoral, intramuscular and subcutaneous delivery. Suitable means for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
[00236] In some embodiments, parenteral formulations are typically aqueous solutions which may contain carriers or excipients such as salts, carbohydrates and buffering agents (preferably at a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyro gen-free water. In other embodiments, any of the liquid
formulations described herein may be adapted for parenteral administration of the conjugates described herein. The preparation of parenteral formulations under sterile conditions, for example, by lyophilization under sterile conditions, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art. In some
embodiments, the solubility of a conjugate as described herein used in the preparation of a parenteral formulation may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
[00237] In some embodiments, formulations for parenteral administration may be formulated for immediate and/or modified release. In some embodiments, active agents in accordance with the present teachings (i.e. , the conjugates described herein) may be
administered in a time release formulation, for example in a composition which includes a slow release polymer. The active agents may be prepared with carriers that will protect the conjugate against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers may be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PGLA). Methods for the preparation of such formulations are generally known to those skilled in the art. In other embodiments, the conjugates in accordance with the present teachings or compositions comprising the conjugates may be continuously administered, where appropriate.
[00238] In some embodiments, a kit is provided. If a combination of active conjugates as described herein is to be administered, two or more pharmaceutical compositions may be combined in the form of a kit suitable for sequential administration or co-administration of the compositions. Such a kit may include two or more separate pharmaceutical compositions, at least one of which contains a conjugate in accordance with the present teachings, and means for separately retaining the compositions, such as a container, divided bottle, or divided foil packet. In some embodiments, compositions comprising one or more conjugates as described herein, in containers having labels that provide instructions for use of the conjugates as described herein for patient selection and/or treatment are provided.
[00239] As used herein, the term "kit" refers to an assembly of materials that are used in performing a method in accordance with the present teachings. The components of the kit may be provided in packaged combination in the same or in separate containers, depending on their cross-reactivities and stabilities, and in liquid or in solid form. The amounts and proportions of components provided in the kit may be selected so as to provide optimum results for a particular application. While in some embodiments, the components to be administered (e.g. , to
a patient) may be provided in separate physical forms (e.g. , a kit containing one or more compositions and one or more fluids), it is to be understood that in other embodiments, all of the components that are to be introduced to the patient may be provided together in one common physical form (e.g., one composition or one fluid).
[00240] The components included in kits in accordance with the present teachings may be supplied in all manner of containers such that the activities of the different components are substantially preserved, while the components themselves are not substantially adsorbed or altered by the materials of the container. Suitable containers include but are not limited to ampoules, bottles, test tubes, vials, flasks, syringes, bags and envelopes (e.g., foil-lined), and the like. The containers may be formed of any suitable material including but not limited to glass, organic polymers (e.g., polycarbonate, polystyrene, polyethylene, polypropylene, etc.), ceramic, metal (e.g. , aluminum), metal alloys (e.g. , steel), cork, and the like. In addition, the containers may contain one or more access ports (e.g., for access via a needle), such as may be provided by a septum. Preferred materials for septa include rubber and polymers including but not limited to, for example, polytetrafluoroethylene of the type sold under the trade name TEFLON by DuPont (Wilmington, Del.). In addition, the containers may contain two or more compartments separated by partitions or membranes that can be removed to allow mixing of the components.
[00241] Kits in accordance with the present teachings may also be supplied with other items known in the art and/or which may be desirable from a commercial and user standpoint, including but not limited to instructions for adding the components of the kit to a heat exchange system.
[00242] Instructional materials provided with kits in accordance with the present invention may be printed (e.g. , on paper) and/or supplied in an electronic-readable medium (e.g., floppy disc, CD-ROM, DVD-ROM, zip disc, videotape, audio tape, etc.). Alternatively, instructions may be provided by directing a user to an Internet web site (e.g., specified by the manufacturer or distributor of the kit) and/or via electronic mail, text message, social media, and/or the like, and combinations thereof.
[00243] In some embodiments, sterile injectable solutions may be prepared by
incorporating the active agent in the required amount in an appropriate solvent with one or a combination of ingredients described above, as required, followed by filtered sterilization. Typically, dispersions are prepared by incorporating the conjugate into a sterile vehicle which contains a dispersion medium and any additional ingredients of those described above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods
of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof, or the ingredients may be sterile-filtered together.
[00244] The composition may be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. In some embodiments, the proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
[00245] Any effective regimen for administering the conjugates described herein may be used. For example, conjugates described herein may be administered as single doses, or the doses may be divided and administered as a multiple-dose daily regimen. Further, a staggered regimen, for example, one to five days per week may be used as an alternative to daily treatment, and for the purpose of the methods described herein, such intermittent or staggered daily regimen is considered to be equivalent to every day treatment and is contemplated. In some embodiments, the patient is treated with multiple injections of a conjugate in accordance with the present teachings to treat the cancer. In some embodiments, the patient is injected multiple times (e.g. , about 2 up to about 50 times) with a conjugate in accordance with the present teachings, for example, at 12-72 hour intervals or at 48-72 hour intervals. Additional injections of a conjugate in accordance with the present teachings may be administered to the patient at an interval of days or months after the initial injections(s) and the additional injections may prevent recurrence of the cancer.
[00246] Any suitable course of therapy with the conjugates in accordance with the present teachings may be used. In some embodiments, individual doses and dosage regimens are selected to provide a total dose administered during a month of about 15 mg. In some examples, a conjugate in accordance with the present teachings is administered in a single daily dose administered five days a week, in weeks 1, 2, and 3 of each 4 week cycle, with no dose administered in week 4. In an alternative example, a conjugate in accordance with the present teachings is administered in a single daily dose administered three days a week, of weeks 1, and 3 of each 4 week cycle, with no dose administered in weeks 2 and 4. In an alternative example, a conjugate in accordance with the present teachings is administered biweekly on weeks 1 and 2 (i.e., on days 1, 4, 8, 11, of a 3-week cycle). In an alternative example, a conjugate described herein is administered and once weekly on weeks 1 and 2 (i.e. , days 1 and 8 of a 3-week cycle).
[00247] The unitary daily dosage of the conjugates in accordance with the present teachings may vary significantly depending on the patient condition, the cancer being treated, the route of administration of the conjugates described herein and tissue distribution, and the possibility of co-usage of other therapeutic treatments, such as radiation therapy or additional drugs in combination therapies. The effective amount to be administered to a patient is based on body surface area, mass, and physician assessment of patient condition. Therapeutically effective doses (also referred to herein as "therapeutically effective amounts") may range, for example, from about 0.5 mg/m 2 to about 20.0 mg/m 2.
[00248] The conjugates in accordance with the present teachings may contain one or more chiral centers, or may otherwise be capable of existing as multiple stereoisomers. Accordingly, it is to be understood that the present invention includes pure stereoisomers as well as mixtures of stereoisomers, such as enantiomers, diastereomers, and enantiomerically or
diastereomerically enriched mixtures. The conjugates in accordance with the present teachings may be capable of existing as geometric isomers. Accordingly, it is to be understood that the present invention includes pure geometric isomers or mixtures of geometric isomers.
[00249] It is appreciated that the conjugates in accordance with the present teachings may exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. The conjugates described herein may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
[00250] In some embodiments, compositions and/or dosage forms for administration of a conjugate in accordance with the present teachings are prepared from a conjugate with a purity of at least about 90%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 99.5%. In other embodiments, compositions and or dosage forms for administration of a conjugate in accordance with the present teachings are prepared from a conjugate with a purity of at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or at least 99.5%.
[00251] The FAP-targeted imaging agents described herein allow the imaging of tumor microenvironment and can allow surgeons to dissect the CAFs cells through fluorescence- guided surgery. The imaging agents described herein in combination with other cancer cell targeted imaging agents can further enhance the outcome of the fluorescence-guided surgery by allowing surgeons to remove the CAFs cells of the tumor microenvironment which cannot be achieved by the cancer cell targeted imaging agents. This can also reduce the chances of tumor
recurrence post-surgery due to leftover CAFs compared to imaging only with cancer cell targeted imaging agents.
[00252] In addition, the agents and methods described herein may open the door for the fluorescence guided surgery of cancers in which the cancer cells themselves do not express the cancer associated antigens such as LHRH-R, folate receptor, PSMA, etc. but the CAFs supporting those cancers express FAP. Dissection of the cells of tumor microenvironment will further contribute to decreasing the recurrence of the cancer post-surgery. In some
embodiments, the FAP-targeted near-infrared dye conjugates may be combined with other cancer cell targeted imaging agents to allow imaging both cancer cells and tumor
microenvironment.
[00253] The FAP-targeted near-infrared dye conjugates described herein may allow for high tumor penetration, low photo bleaching, and high signal to noise ratio in addition to the targeting specificity of FAP inhibitor. In addition, the dye conjugates may rapidly clear from the receptor negative tissues. Since FAP is expressed in CAFs of most solid tumors, FAP targeted NTR dyes may be used for imaging many types of cancers.
[00254] The following examples and representative procedures illustrate features in accordance with the present teachings, and are provided solely by way of illustration. They are not intended to limit the scope of the appended claims or their equivalents.
[00255] Materials. Benzotriazol-l-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop), N,N-Dimethylmethanamide (DMF), N-ethyl-N-isopropylpropan-2-amine (DIPEA), isopropyl alcohol (IPA,) dichloromethane (DCM) and trifluoroacetic acid (TFA), 1,2- ethanedithiol, triisopropylsilane (TIPS), and all other chemical reagents were purchased from Sigma- Aldrich. Cell culture reagents such as rosewell park memorial institute medium 1640 (RPMI 1640) was purchased from GIBCO whereas fetal bovine serum (FBS), 1% penicillin- streptomycin, 2Mm glutamine were purchased from Life Technologies.
[00256] Compound Examples
[00257] Scheme 1. Synthesis of fibroblast activation protein a (FAP) ligand JFL. Reagents and conditions a) HATU, Anhy. DIPEA, Any. DMF, rt; b) TFAA, Anh. DCM, Anhy. Pyrine, rt; c) TFA, rt; d) HATU, Anhy. DIPEA, Anhy. DMF, rt; e) TFA, rt.
[00258] Synthesis of JFL was initiated by coupling compound 1 and 2 by using HATU as coupling agent to yield compound 3. The amide group on compound 3 was converted to nitrile (compound 4) by using TFAA. Compound 4 was then subjected to Boc deprotection followed by coupling with compound 6 to yield the yield compound 7. Compound 8 was obtained by deprotecting the Boc group on compound 7. Compound 8 is alternatively referred to herein as the FAP ligand JFL.
[00259] Compound 3. To a solution of 1 in anhydrous DMF lequivalnce of compound 2 and HATU was added. To the above solution anhydrous DIPEA (5 eq) was added and stirred under argon atmosphere for 6 h. The crude product was purified using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 7.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the requisite product. LRMS-LC/MS (m/z): [M+H]+ calcd for Ci3H2iF2N304, 321.32; found 323. LC/MS trace of Compound 3 is shown in Figure 1.
[00260] Compound 4. The HPLC purified compound 3 was dissolved in anhy. DCM. To this solution was added anhydrous pyridine (1 eq) followed by TFAA (1 eq). The reaction mixture was stirred at room temperature for 1 h. Completion of the reaction was monitored by LC/MS. The crude product was purified using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 7.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the requisite product. LRMS-LC/MS (m/z): [M+H]+ calcd for Ci3Hi9F2N303, 303.31; found 305. LC/MS trace of Compound 4 is shown in Figure 2.
[00261] Compound 7. Compound 4 was dissolved in TFA and stirred at room temperature for 30 min. Completion of the reaction was monitored through LC/MS. TFA was evaporated by using rotary evaporator and the compound 5 was dried under high vacuum and used further
without any purification. LC/MS trace of Compound 5 is shown in Figure 3. To a solution of compound 5, compound 6 (1 eq) and HATU (1 eq) in DMF DIPEA (5 eq) was added and stirred under argon atmosphere for 6 h. The completion of the reaction was monitored by LC/MS. The crude compound 7 was purified using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 7.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the requisite product. LRMS-LC/MS (m/z): [M+H]+ calcd for C2oH25F2N504,437.45; found 438. LC/MS trace of Compound 7 is shown in Figure 4.
[00262] Compound 8. Compound 7 was dissolved in TFA and stirred ad room temperature for 30 min. TFA was removed by using rotary evaporator and the crude compound 8 was used for the next reaction without any further purification. LRMS-LC/MS (m/z): [M+H]+ calcd for
5.
JFL-L1
d
[00263] Scheme 2. Synthesis of JFL-L1-S0456 and JFL-L1-FM. Reagents and conditions: a) (i) HATU, Anhy. DIPEA, Anhy. DMF, rt. (ii) TFA, rt; b) (i) PyBop, Anhy. DMF, Any. DIPEA, rt. (ii) TFA/H20/TIPS/EDT (92.5:2.5:2.5:2.5), 1 h; c) DMSO, DIPEA, S0456 maleimide, rt; d) DMSO, DIPEA, fluorescein maleimide, rt.
[00264] Compound 8 was linked to a spacer and is designated herein as JFL-L1. The ligand was linked to the linker partially in solution phase and by standard solid phase peptide synthesis. This was then coupled with the maleimide derivatives of FM or S0456 to yield JFL- Ll-FM or JFL-L1-S0456 respectively. Intermediates and final conjugates were purified by HPLC and characterized by using LC/MS and UPLC.
[00265] Compound 10. To the solution of compound 8 in anhy. DMF was added, compound 9 (1 eq), HATU (1 eq) and DIPEA (10 eq). The reaction mixture was stirred under argon atmosphere for 6 h. The completion of reaction was monitored by LC/MS. The crude compound 10 was purified by using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 7.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the requisite product. LRMS-LC/MS (m/z): [M+H]+ calcd for Ci9H2iF2N505,437.4; found 438. LC/MS trace of Compound 10 is shown in Figure 6.
[00266] Synthesis ofJFL-Ll . As described in scheme 2, the compound was prepared by solid phase peptide synthesis. PyBop, Anhy. DMF, Anhy. DIPEA, compound 10, and the H- Cys(Trt)2-chlorotrityl resin were combined at room temperature. The final product was cleaved from the resin using the standard cocktail solution of TFA:Water:TIPS: Ethanedithiol (95%: 2.5%: 2.5%: 2.5%). Crude JFL-L1 was purified by using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 5.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the
requisite product. LRMS-LC/MS (m/z): [M+H]+ calcd for C22H26F6N606S, 540.54; found 541. LC/MS trace of JFL-L1 is shown in Figure 7.
[00267] Synthesis ofJFL-Ll -FM and JFL-L1 -S0456. JFL-L1 was dissolved in DMSO and 5 eq of DIPEA. To this reaction mixture was added either 1 eq of fluorescein maleimide or S0456 maleimide. The reaction mixture was stirred under argon atmosphere for 1 h and the completion of the reaction was monitored by LC/MS. The crude compounds JFL-Ll-FM and JFL-L1-S0456 were purified by using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 7.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the requisite product. The LCMS characterization of JFL-Ll-FM and JFL-L1-S0456 are as follows. LRMS-LC/MS (m/z): [M+H]+ calcd for C46H39F2N7Oi3S, 967.91; found 968. LRMS-LC/MS (m/z): [M+H]+ calcd for CTsHssFiNioNasOiiSs, 1745.82.35; found 1747. LC/MS trace of JFL-Ll-FM is shown in Figure 8. LC -L1-S0456 is shown in Figure 9.
[00268] Scheme 3. Synthesis of S0456 maleimide. Reagents and conditions: a) KOH, H20, rt-100 °C; b) HATU, Anhy. DIPEA, Anhy. DMF, rt. LC/MS trace of S0456 maleimide is shown in Figure 10.
[00269] Synthesis ofFAPa Targeted Tubulysin B hydrazide
[00270] Scheme 4. Synthesis of JFL-Ll-TubBH, Reagents and conditions: a. (i) JFL-L1,
H20/NaHC03 (pH= 7.0-7.2), Argon, r.t. (ii) activated TubBH, anhydrous THF, argon, r.t.
[00271] FAP targeted tubulysin B hydrazide conjugate was synthesized as described below. Briefly, JFL-Ll was dissolved in argon purged HPLC grade water and adjusted to pH 7.0 using a NaHC03 saturated solution of the same water. Disulfide activated tubulysin B hydrazide(l eq) in THF was added to the reaction mixture and stirred at room temperature under argon atmosphere. The progress of the reaction was monitored by analytical LRMS- LCMS. The crude product was purified by using preparative RP-HPLC [A=2 Mm ammonium acetate buffer (pH 7.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield 95% of the desired product. LRMS-LC/MS (m/z): [M+H]+ calcd for C67H93F2Ni3Oi7S3, 1487; found [M/2 +1] 744, as shown in Fig. 17.
[00272] Synthesis of FAP targeted NIR imaging: PEG and peptidoglycan linker
[00273] Scheme 5. Synthesis of JFL-L2-S0456. Reagents and conditions: a) DMSO, DIPEA, S0456 maleimide, rt.
[00274] Synthesis of JFL-L2-S0456: FAP targeting ligand (JFL) was conjugated with a PEG and a peptidoglycan molecule to synthesize JFL-L2. Briefly, JFL-L2 was synthesized by standard solid phase peptides synthesis and purified by RP-HPLC as shown in Fig. 21A.
LRMS-LC/MS (m/z): [M+H]+ calcd for C48H75F2N9Na302oS, 1168; found 1169, as shown in
Fig. 21B. To the reaction mixture of 1 equivalence of purified JFL-L2 and S0456-maleimde in anhydrous DMSO, 5 equivalences of DIPEA was added. The reaction mixture was allowed to stir under argon atmosphere and the completion of the reaction was monitored by using LC-MS. Crude JFL-L2-S0456 was purified by using RP-HPLC [A=2 mM ammonium acetate buffer (pH 7.0), B= acetonitrile, solvent gradient 0% B to 50% B in 35 min] to yield the requisite product. LRMS-LC/MS (m/z): [M+H]+ calcd for CioiHis^NisNasOseSs, 2371.5; found 790.
[00275] Synthesis of JFL-L3
[00276] Scheme 6 Synthesis of JFL-L3, Reagents and conditions: (a) (i) 20%
piperidine/DMF, rt, (ii) Fmoc-Asp(OtBu), PyBop, DMF, DIPEA, (b) (i) 20% piperidine/DMF, rt,10 min (ii) Fmoc-diaminopropionic (DAP) acid, PyBop, DMF, DIPEA, (c) (i) 20%
piperidine/DMF, rt, (ii) Fmoc-8-amino-octanoic acid, PyBop, DMF, DIPEA, (d) (i) 20% piperidine/DMF, rt,10 min (ii) Compound 10, PyBop, DMF, DIPEA, (iii) TFA/H20/TIPS/EDT (92.5:2.5:2.5:2.5), 1 h. * The crude product was purified by using HPLC and characterized by using LC/MS.
[00277] Synthesis of JFL-L3: As described in the scheme, the JFL-L3 was synthesized by standard solid phase peptide synthesis. All the components of the conjugate were built on the H-Cys(Trt)2-chlorotrityl resin. The standard cocktail solution of
TFA:Water:TIPS:Ethanedithiol (95%: 2.5%: 2.5%: 2.5%) was used to cleave the final conjugate from the resin. Crude products were purified by using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 5.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the requisite product. For JFL-L3, LRMS-LC/MS (m/z): [M+H]+ calcd for
C37H52F2N10O11S, 882.9; found 882, as shown in Fig. 25A.
[00278] Formulation of non-radioactive JFL-L3: Prior to radiolabeling with 99mTc the JFL- L3 was formulated according to previously published procedure. Briefly, the 0.1 mg of. JFL- L3, 80 mg of sodium a-D-glucoheptonate, and 10 mg of tin (II) hydrochloride, were dissolved in argon purged water. The pH of the solution was adjusted to 6.8 +0.2 with sodium hydroxide or hydrochloric acid. The final volume was adjusted to 10 ml and then transferred to 10 vials containing 1 ml each of the above solution and lyophilized. The lyophilized powder was sealed in the vials under argon and stored at -20 °C.
[00279] 99mTc labelling of JFL-L3: Radiolabeling of the conjugate was performed according to the published procedure. Briefly, to a formulated vial of JFL-L3 1 ml of 99mTc sodium pertechnetate was added and heated for - 18 min at 100 °C. The chelated solution was cooled to room temperature prior to using it for in vitro and in vivo studies. The chelation efficiency of the conjugates was confirmed by radio HPLC, as shown in Fig. 25B.
[00280] Synthesis of JL-L3-S0456
[00281] Scheme 7. Synthesis of JL-L3-S0456, Reagents and conditions: (a) (i) 20% piperidine/DMF, rt, (ii) 3,4,5,6-di-isopropylidene- l-amino-deoxy(Fmoc-Glu-OH)-D-glucitol, PyBop, DMF, DIPEA, (b) (i) 20% piperidine/DMF, rt,10 min (ii) Fmoc-Glu(OtBu)-OH, PyBop, DMF, DIPEA, (c) (i) 20% piperidine/DMF, rt, (ii) 3,4,5,6-di-isopropylidene-l-amino- deoxy(Fmoc-Glu-OH)-D-glucitol, PyBop, DMF, DIPEA, (d) (i) 20% piperidine/DMF, rt,10 min (ii) Fmoc-8-amino-octanoic acid, PyBop, DMF, DIPEA, (e) (i) 20% piperidine/DMF, rt,10 min (ii) JL, PyBop, DMF, DIPEA, (iii) TFA/H20/TIPS/EDT (92.5:2.5:2.5:2.5), 1 h, (f) JL-L3, S0456 maleimide, anhydrous DMSO, DIPEA, rt.
[00282] Synthesis of JL-L3: As described in Scheme 7, the linker was prepared by the standard solid phase peptide synthesis. The peptidoglycan subunit was synthesized as described elsewhere. JL was then coupled to the linker on the solid phase. The final product was cleaved from the H-Cys(Trt)2-chlorotrityl resin using the standard cocktail solution of
TFA:Water:TIPS: Ethanedithiol (95%: 2.5%: 2.5%: 2.5%). Crude JL-L3 was purified by using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 5.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the requisite product. LRMS-LC/MS (m/z): [M+H]+ calcd for C67H94F2Nio023S, 1477; found 1478.
[00283] Synthesis ofNIR conjugate JL-L3-S0456: S0456 dye containing the maleimide was synthesized as described in the Scheme 3. 1 equivalence of S0456-maleimide and JL-L3 were dissolved in anhydrous DMSO, followed by addition of 5 equivalences of DIPEA. The
reaction mixture was stirred under argon atmosphere for lh. The completion of the reaction was monitored by using LC-MS. Crude JL-L3-S0456 was purified by using RP-HPLC [A=2 Mm ammonium acetate buffer (pH 7.0), B= acetonitrile, solvent gradient 0% B to 80% B in 35 min] to yield the requisite product. The LCMS characterization of JL-L3-S0456 was as follows. LRMS-LC/MS (m/z): [M+H]+ calcd for CiioHis^N^NasOsgSs, 2680.85; found 2682.
[00284] Method Examples
[00285] Cell Culture. The cancer cells FaDu, HT29, MDA-MB231, and KB cells were cultured in a medium consisting RPMI 1640, 10% FBS, 1% penicillin-streptomycin, 1 % 2 mM glutamine at 37°C in a 5% C02 and 95% humidified atmosphere. HEK 293 cells were transfected to generate HEK293-FAP. The FAP positive cells were cultured in DMEM medium supplemented with 2μ1/ιη1 of puromycin, 10% FBS, 1% penicillin-streptomycin, 1 % 2 mM glutamine at 37°C in a 5% C02 and 95% humidified atmosphere.
[00286] Confocal Microscopy. FaDu, HT29, MDA-MB231 and KB cancer cells (30,000) were plated on 4 well confocal plate. The cells were incubated with 100 mM JFL-L1-FM and incubated for 1 h. The unbound fluorescence was removed by washing the cells three times with the medium. The cell bound fluorescence was observed by using Olympus confocal microscopy.
[00287] In Vitro Binding Assay. 100,000 HEK293-FAP cells were seeded in an amine coated 24 well plate. The cells were allowed to grown as a monolayer over 24 h and incubated with various concentrations of the JFL-L1-S0456 either in the presence or absence of excess of JFL-L1. After incubating for 1 h the cells were washed three times with medium to remove to unbound fluorescence. The cells were dissolved in 1% SDS and the cell bound fluorescence was measured by using a fluorimeter.
[00288] Animal Husbandry. 5-6 weeks old female athymic nu/nu mice were purchased from Harlan Laboratories. The animals had access to normal rodent chow and water ad libitum. The animals were housed in standard 12 h light-dark cycles. All animal procedures were approved by the Purdue Animal Care and Use Committee.
[00289] In Vivo Fluorescence Imaging and Biodistribution. For the development of subcutaneous tumor xenografts, MDA-MB231, OVCAR-3 and HEC-1B 5 x 106 cells in 0.2 ml sterile PBS were injected subcutaneously in the right hind flank of the female nu/nu mice.
Tumor imaging was initiated once the tumor volume reached between 200 mm 3 and 300 mm 3. Each tumor-bearing mouse was intravenously injected (via tail vein) with 10 nanomoles of fluorescence dye conjugate either in the presence or absence of a 100-fold excess of the unlabeled conjugate. Animals were euthanized two hours post injection using C02 and the
images were acquired using Caliper IVIS Luminal II. After performing the whole body image, the organs of interest were harvested and imaged to inspect the accumulation of the
fluorescence in these organs. The image acquisition parameters were as follows: i) lamp level- high, ii) excitation-745 nm, iii) emission-ICG, iv) binning (M) 4M, (v) f-stop- 4, (vi) FOV-12.5, (vii) acquisition time, 5 s.
[00290] In Vitro Binding Affinity and Confocal Imaging. The cancer cells FaDU, HT29, MDA-MB231 and KB were investigated for the expression of FAP. For this purpose, the cancer cells were seeded on a confocal well plate and incubated with 100 nM of the FAP targeted FM conjugate (JFL-L1-FM) After 1 h incubation at 37 °C the cells were washed to remove any excess of the un were observed under confocal microscopy to investigate any uptake of the dye, as shown in Figure 11. In all the four cell types no uptake of dye conjugate was observed. This implied absence of FAP on these cancer cells.
[00291] To find the binding affinity of the FAP targeted NIR dye conjugate (JFL-L1- S0456), the FAP transfected HEK293 cells were plated on amine coated 24 well plate and incubated with various concentrations of the dye conjugate either in the presence or absence of excess of the FAP ligand JFL. After 1 h of incubation cells were washed to remove any excess of the unbound dye. The cells were dissolved in 1% SDS followed by quantification of cell bound fluorescence using a fluorimeter. To quantify the fluorescence, the samples were excited at 745 nm and measuring the emission of 790 nm. Cell bound fluorescence was plotted against various concentrations by using the Graph pad prism to find the apparent KD value, as shown in Figure 12. The apparent dissociation constant of JFL-L1-S0456 was about 3.5 nM. When incubated with NIR dye conjugate in the presence of excess of JFL the cell bound fluorescence was competed indicating the uptake of JFL-L1-S0456 was FAP mediated.
[00292] In Vivo Fluorescence Imaging. To investigate the ability of JFL-L1-S0456 to accumulate in vivo mice were implanted with FaDu (n=5), HT29 (n=5), MDA-MB231(n=5) or KB (n=5) cells. These tumor bearing mice were intravenously injected with the NIR dye conjugate alone or co-injected with excess of the FAP targeting ligand JFL. After 2 h post injection the mice were euthanized and imaged, as shown in Figures 13A and 13B (FaDu), Figures 14A and 14B (KB), Figures 15A and 15B (HT29), and Figures 16A and 16B (MDA- MB231). FAP mediated uptake of the dye conjugate was observed in all the tumor types and excess of JFL was able to compete the fluorescence in the tumor. To inspect the uptake of the dye conjugate in other organs necropsy was performed to harvest the organs and imaged, as shown in Figures 13C and 13D (FaDu), Figures 14C and 14D (KB), Figures 15C and 15D (HT29), and Figures 16C and 16D (MDA-MB231) (organs from top to bottom: tumor, heart,
lungs, spleen, pancreas, muscle, stomach, small intestine, large intestine, liver, and kidney). In addition to tumor a minimal or no uptake of the dye conjugate was observed in the liver and kidney. The uptake in these organs was not receptor mediated and was largely due to excretion of the conjugate via renal or hepatic route. Without intending to be bound by theory, since the cancer cells are FAP negative the in vivo uptake of the NIR dye conjugate is expected to be as a consequence of accumulation in the cancer-associated fibroblast which are known to express FAP. When tested in vivo, the FAP-targeted dye conjugate showed FAP mediated uptake in the tumor. Other organs (kidney and liver) showed either minimal or no uptake of the near-infrared dye conjugate.
[00293] In vivo therapy study MDA-MB231: 5-6 weeks old female nu/nu athymic nude mice were subcutaneously injected with 5 million breast cancer cells (MDA-MB-231) into their shoulders. Tumors were measured in two perpendicular directions either daily or every other day during the treatment with Vernier calipers, and their volumes were calculated as 0.5 x L x W , where L is the longest axis (in millimeters), and W is the axis perpendicular to L (in millimeters). Once the tumor volume reached ~ 100 mm the mice were randomly divided into various groups and the treatment was initiated. Dosing solutions were prepared in sterile saline and injected intravenously via tail vein. Mice in control group were injected with sterile saline whereas mice in treatment arms were injected with 40 nmoles of JFL-Ll-TubBH either daily or every other day. In addition to receiving 40 nmoles of JFL-Ll-TubBH the mice in competition group were also administered with 100-fold excess of the FAP-targeted ligand conjugated to the linker (JFL-L1), as shown in Fig. 18A. Mice were weighed as a measure of gross toxicity at each dosing, as shown in Fig. 18B.
[00294] To investigate the in vivo efficacy of FAP targeted Tubulysin conjugate MDA- MB-231 tumor xenografts were treated with JFL-L1-S0456. During the therapy period the mice in control and competition arm did not show any reduction in tumor volume. In the treatment arm mice were dosed with 40nmoles of JFL-Ll-TubBH and divided into two separate groups depending on the frequency of the administration of the therapeutic agents. When compared to control and competition group mice in both the therapy groups showed significant decrease in tumor volume. Mice which were treated with JFL-Ll-TubBH every other day did not show complete response rather a delayed tumor growth was observed. On the other hand when the mice were treated with same dose of JFL-Ll-TubBH daily, a complete response was observed. Throughout the study weight of the mice were monitored as a measure of gross toxicity. Mice in saline, completion and treatment group that received JFL-Ll-TubBH every other day did not show any decrease in weight. The mice which were treated with the FAP targeted tubulysin
displayed an approximately 5 % reduction in weight but the same mice gained the weight towards the end of the treatment.
[00295] In vivo combination therapy with FAP targeted TubBH and folate targeted PI3Kinase inhibitor or TLR7 agonist:
[00296] 4-5-week-old Female BALB/c mice were injected with 100,000 4T1 cells close to the mammary fat pad. Once the tumor volume reached ~ 100 mm the mice were randomly divided into various groups and treatment was initiated. Dosing solutions of FAP targeted tubulysin B hydrazide conjugate (JFL-Ll-TubBH), folate targeted PI3 Kinase inhibitor (FA- PI3K), and folate targeted TLR7 antagonist (FA-TLR7) were prepared in sterile saline and injected intravenously via tail vein. The mice in control group were administered with sterile saline whereas mice in treatment group either received the JFL-Ll-TubBH or FA-PI3K or FA- TLR7 alone or in combination with one of the other agents (JFL-Ll-TubBH, FA-PI3K, or FA- TLR7). The concentration of single dose used for the treatment were 20 nmoles of JFL-Ll- TubBH, 10 nmoles of FA-PI3K and 10 nmoles of FA-TLR7. Mice were injected with the test agents daily followed by tumor volume measurement (caliper). As a measure of gross toxicity, body weight of the mice was also monitored at each dosing. Mice in FAP competition group received FAP targeted tubulysin B hydrazide in the presence of excess of the FAP ligand, JFL.
[00297] 4T1 tumor bearing mice in control and competition (FAP- competition) group did not show any reduction in tumor volume, as shown in Fig. 19A. Compared to these two group mice treated with single agent either FAP targeted tubulysin B hydrazide (JFL-Ll-TubBH) or folate targeted PI3 Kinase inhibitor (FA-PI3K) or TLR7 antagonist (FA-TLR7) delayed the tumor growth. To investigate the effect of combination therapy of FAP and folate targeted chemotherapeutic agents mice in combination therapy arm were divided into two different groups. One of the group received JFL-Ll-TubBH in combination with FA-TLR whereas mice in the other group received FA-PI3K along with JFL-Ll-TubBH. When compared to the single agent treatment both the combination therapy showed a decrease in tumor volume that was additive. Throughout the therapy weight of the mice were monitored as a measure of gross toxicity. None of the group exhibited any weight loss, as shown in Fig. 19B.
[00298] In vivo FAP targeted CAR T-cell therapy: MDA-MB-231 subcutaneous tumor was developed in female NSG mice by injecting 5 million cancer cells. Once the tumor volume reached ~ 100 mm the mice were randomized into three different groups and treatment was initiated. Mice in all the groups were administered with 15 million CAR T-cells which has an scFv domain that binds specifically and tightly with fluorescein. 2 h after administration of the CAR T-cells mice in all the groups were given the first dose of the respective test agents. Mice
in the control group were injected with sterile saline whereas mice in treatment arm were either injected with JFL-Ll-FM (10 nmoles) alone or in combination with 100-fold excess of FAP ligand, JFL. During therapy, mice in different groups were administered with the respective test agents intravenously on every other day. As a measure of gross toxicity mice were also weighed at every dosing.
[00299] MDA-MB-231 mice xenograft models were utilized to investigate the effect of CAR T-cell with an scFV domain that recognizes the fluorescein fragment of the FAP targeted FM conjugate (JFL-Ll-FM). The mice in control and competition group did not show any difference in the tumor growth rate, as shown in Fig. 20A. At the beginning of the study mice treated with CAR T-cell and FAP targeted FM (JFL-Ll-FM) did not display any reduction in tumor volume. But after 1 week of treatment slight separation in the tumor growth rate was observed. No weight loss was observed in any of the arms of the study, as shown in Fig. 20B. The results suggests that FAP targeted CAR T-cell therapy has the potential to kill the tumor but the dose of CAR T-cell and JFL-Ll-FM needs to be optimized to induce tumor suppression earlier in the treatment.
[00300] In vivo Imaging with JFL-L2-S0456: MDA-MB-231 tumor bearing athymic female mice were injected with 5 nmoles of JFL-L2-S0456 intravenously. Mice were euthanized 2 h post-injections using C02 and the images were acquired using IVIS Lumina II. After completion of whole body imaging the organs were harvested and further imaged to examine the accumulation of the JFL-L2-S0456 in these organs.
[00301] MDA-MB-231 xenograft was exploited to investigate the in vivo imaging ability of FAP targeted NIR conjugate consisting of PEG and peptidoglycan linker, JFL-L2-S0456, as shown in Figs. 22A-C. Whole body imaging revealed that after 2 h post-injection the conjugate was found to be accumulated in the tumor. Biodistribution of vital organs/tissue further confirmed that tumor had the highest uptake of the dye conjugate. Followed by tumor the other two organs that displayed the uptake of JFL-L2-S0456 were liver and kidneys. The uptake in kidney was higher when compared to the liver. Kidney and liver plays a vital role in excretion of small molecules. The data suggests that the uptake of the FAP targeted dye conjugate in these organs was due to excretion of the fluorescent conjugate via renal and hepatic routes. No uptake was observed in any other organs.
[00302] In vivo imaging using different concentrations of JFL-L1 -S0456: MDA-MB-231 tumor bearing female athymic nude mice were intravenously injected with 5, 10 or 20 nmoles of JFL-L1-S0456. After 2 h the mice were euthanized using C02 and imaged with IVIS Lumina
II. After completing the whole-body imaging biodistribution was performed and the organs were imaged to examine the accumulation of JFL-L1-S0456, as shown in Fig. 23.
[00303] To investigate the uptake of JFL-L1-S0456 in a dose dependent manner MDA- MB-231 tumor xenografts were administered with the 5, 10 and 20 nmoles of the dye conjugate. A direct correlation between increasing dose and increase in fluorescence intensity of the tumor was observed. When compared to the mice in 5 nmole group a two-fold increase in the fluorescence intensity of tumor was observed in 10 nmole group. The fluorescence intensity of the tumor in 5 and 10 nmole group were found to be in 10 range whereas the uptake in 20nmole group was in 10 . Thus, the fluorescence intensity of the tumor was found to be increased with administration of higher dose of JFL-L1-S0456 and did not show any signs of saturation up to 20 nmoles.
[00304] Cocktail Imaging: FAPa and LHRH-R targeted NIR conjugates
[00305] Female athymic mice were implanted with MDA-MB-231 cancer cells to develop subcutaneous tumors. Tumor bearing mice were intravenously injected either with FAP targeted NIR conjugate, JFL-L1-S0456 alone (5 nmoles) or Luteinizing hormone-releasing hormone receptor targeted NIR conjugate, JL-L3-S0456 (5 nmoles) alone or with both the conjugates. 2 h post-injection the mice were euthanized using C02 and imaged with Caliper IVIS Lumina II, as shown in Fig. 24A. Followed by completion of whole body imaging biodistribution was performed and all the organs were imaged to examine the uptake of the dye conjugates, as shown in Fig. 24B.
[00306] The feasibility of using FAP-targeted NIR dye (JFL-L1-S0456) and Luteinizing hormone-releasing receptor(LHRH-R) targeted NIR dye (JL-L3-S0456) to image cancers expressing both FAP and LHRH-R was evaluated. When injected with JFL-L1-S0456 or JL- L3-S0456 alone the uptake of the dye conjugates in MDA-MB-231 tumor was found to be in the similar intensity range. When the same tumor type was co-administered with the identical dose of JFL-L1-S0456 and JL-L3-S0456 an increase in the fluorescence intensity of the tumor was observed. When compared to the single agent group (JFL-L1-S0456 or JL-L3-S0456 alone) the increase of the intensity in the combination group was more than double. The results suggests that cocktail imaging by combining FAP and LHRH-R targeted imaging agents can be efficiently used to provide better image of the tumors that are positive for both the targets.
[00307] In vitro binding study using 99mTc labeled JFL-L3: Human FAPa transfected
HEK-293 cells were seeded in amine coated 24 well plated and allowed to grow as monolayer. The spent medium was replaced with medium containing various concentrations of the 99mTc labeled FAP conjugate (JFL-L3). For the blocking study, the cells were treated with 99mTc
labeled JFL-L3 in the presence of excess of JFL. After incubating for 2 h the cells were washed three times with culture medium to remove the unbound radioactive conjugate and dissolved in 0.5 ml of 0.25 N NaOH. Cell bound radioactivity was counted using gamma scintillation counter. The apparent KD was determined by analyzing the data using Graph Pad Prism and is shown in Fig. 26.
[00308] In vivo radioactive imaging: MDA-MB-231 tumor bearing athymic nude mice
(female) were intravenously injected with 150 μθ of 99mTc labeled JFL-L3 alone or in the presence of 100-fold excess of JFL. After 2 h mice were sacrificed by C02 asphyxiation, and imaged with KODAK Image Station, as shown in Fig. 27A. The parameters used for radioimaging were: acquisition time = 2 min, f-stop = 4, focal plane = 7, FOV = 200, binning = 4. For white light imaging, the parameters were: acquisition time = 0.05 s, f-stop = 11, focal plane = 7, FOV = 200, with no binning. For the biodistribution study necropsy was performed to collect the organs/blood/tissues. Radioactivity associated with all the organs/blood/tissues was counted by using gamma counter.
[00309] FAP targeted conjugate (JFL-L3) for 99mTc radioactive imaging was synthesized by standard solid phase peptide synthesis. When tested in vitro in HEK cells-transfected with human FAP the 99mTc labeled JFL-L3 displayed low nanomolar binding (KD) of 10.5 nM. Following the in vitro study in vivo targeting of the 99mTc labeled JFL-L3 was investigated in MDA-MB-231 tumor xenografts by administering the radiolabeled compound intravenously, as shown in Fig. 27B. FAP targeted radioactive conjugate was observed to accumulate in the tumor and kidney. Other than the tumor and kidney other organs displayed very low to no uptake of the radiolabeled compound. In the comptetion study excess of the JFL was found to block the tumor uptake of 99mTc labeled JFL-L3 in the tumor indicating that the accumulation of the radiotracer in the tumor was FAP mediated. On the contrary the uptake in the kidney was not blocked by administration of excess of JFL, as shown in Fig. 27C. This suggested that the uptake of the radiotracer in the kidney is rather non-specific. Since small hydrophilic molecules are often excreted by renal route the uptake in the kidney might be transient. This data suggests that 99mTc labeled JFL-L3 can accumulate in the tumor expressing FAP while causing minimal damage to the organs lacking the target antigen.
[00310] The entire contents of each and every patent publication, non-patent publication, and reference text cited herein are hereby incorporated by reference, except that in the event of any inconsistent disclosure or definition from the present specification, the disclosure or definition herein shall be deemed to prevail.
[00311] It is to be understood that use of the indefinite articles "a" and "an" in reference to an element does not exclude the presence, in some embodiments, of a plurality of such elements.
[00312] The foregoing detailed description and the accompanying drawings have been provided by way of explanation and illustration, and are not intended to limit the scope of the appended claims. Many variations in the presently preferred embodiments illustrated herein will be apparent to one of ordinary skill in the art, and remain within the scope of the appended claims and their equivalents.
[00313] It is to be understood that the elements and features recited in the appended claims may be combined in different ways to produce new claims that likewise fall within the scope of the present invention. Thus, whereas the dependent claims appended below depend from only a single independent or dependent claim, it is to be understood that these dependent claims can, alternatively, be made to depend in the alternative from any preceding claim— whether independent or dependent— and that such new combinations are to be understood as forming a part of the present specification.
Claims
WHAT IS CLAIMED IS:
1. A conjugate, or a pharmaceutically acceptable salt thereof, having a structure
B-L-X,
wherein B comprises a fibroblast activation protein (FAP) inhibitor;
L comprises a bivalent linker; and
X comprises a near infrared (NIR) dye, a radioactive imaging agent, or a therapeutic agent effective against cancer cells and/or cancer- associated fibroblasts (CAF).
2. The conjugate of claim 1, wherein B has a structure
wherein R 1 and R 2 are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Ci-C4 alkyl;
R is a Ci-C4 alkyl, nitrile, or isonitrile;
R4, R5, and R6 are the same or different, and are each independently selected from the group consisting of hydrogen, halogen, and Ci-C4 alkyl; and
n is an integer from 1 to 8.
3. The conjugate of claim 2, or a pharmaceutically acceptable salt thereof, wherein each of R 1 and R 2 is a halogen.
4. The conjugate of claim 2, or a pharmaceutically acceptable salt thereof, wherein each of R 1 and R 2 is fluorine.
5. The conjugate of claim 2, or a pharmaceutically acceptable salt thereof, wherein R is nitrile.
6. The conjugate of claim 2, or a pharmaceutically acceptable salt thereof, wherein each of R4, R5, and R6 is hydrogen.
7. The conjugate of claim 2, or a pharmaceutically acceptable salt thereof, wherein B has a structure
8. The conjugate of claim 2, or a pharmaceutically acceptable salt thereof, wherein B has a structure
9. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the linker comprises at least one amino acid in the D- or L- configuration, or a derivative thereof, selected from the group consisting of Lys, Asn, Thr, Ser, He, Met, Pro, His, Gin, Arg, Gly, Asp, Glu, Ala, Val, Phe, Leu, Tyr, Cys, and Trp.
10. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the linker comprises at least two amino acids, or a derivative thereof, independently selected from the group consisting of Glu and Cys.
11. The conjugate of claim 10, or a pharmaceutically acceptable salt thereof, wherein the amino acid derivative is a glutamic acid having an amino sugar moiety covalently attached to the side chain carboxylic acid to form an amide bond.
12. The conjugate of claim 11, or a pharmaceutically acceptable salt thereof, wherein the amino sugar moiety is 1-deoxy-l-amino-D-glucitol.
13. The conjugate of claim 9, or a pharmaceutically acceptable salt thereof, wherein the linker comprises an amino acid portion of the formula Glu-Glu-Glu, wherein the glutamic acids are optionally substituted with an amino sugar moiety covalently attached to the side chain carboxylic acid to form an amide bond.
14. The conjugate of claim 14, or a pharmaceutically acceptable salt thereof, wherein the amino sugar moiety is 1-deoxy-l-amino-D-glucitol.
15. The conjugate of claim 14, or a pharmaceutically acceptable salt thereof, wherein the Glu-Glu-Glu are covalently bonded to each other through the carboxylic acid side chains.
16. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the linker comprises a moiety of the formula
wherein m is an integer from 0 to 9, p is an integer from 3 to 10, q is an integer from 3 to 100.
17. The conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the linker comprises a portion selected from the group consisting of
wherein
7 8
each of R and R is independently H or Ci-C6 alkyl;
t is an integer from 1 to 8.
18. The conjugate of claim 17, or a pharmaceutically acceptable salt thereof, wherein the linker is of the formula
19. The conjugate of claim 17, or a pharmaceutically acceptable salt thereof, wherein R 7 and R 8 are H; and t is 2.
20. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the linker comprises a hydrazine
21. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein L comprises a structure
22. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, the linker comprises a portion selected from the group consisting of
wherein R is H or Ci-C6 alkyl.
23. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, comprising the formula
24. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein X comprises a fluorescent dye.
25. The conjugate claim 1, or a pharmaceutically acceptable salt thereof, wherein X comprises a NIR dye.
26. The conjugate of claim 24, or a pharmaceutically acceptable salt thereof, wherein the fluorescent dye is fluorescein maleimide or fluorescein isothiocyanate (FITC).
27. The conjugate of claim 25, or a pharmaceutically acceptable salt thereof, wherein the NIR dye is S0456.
28. The conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, claim 1 wherein X has a structure
The conjugate of claim 1 having a structure
or a pharmaceutically acceptable salt thereof.
31. The conjugate of claim 1 having a structure
or a pharmaceutically acceptable salt thereof.
32. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is a chelating agent of the formula
33. The conjugate of claim 32, or a pharmaceutically acceptable salt thereof, wherein X comprises a radioactive metal isotope coordinated to the chelating agent.
4. A conjugate having a structure
wherein L comprises a bivalent linker; and
X comprises a near infrared (NIR) dye.
35. The conjugate of claim 34 having a structure
36. A method of surgically removing cancer-associated fibroblasts (CAFs) from a patient, the method comprising:
delivering a conjugate to a tumor microenvironment of the patient, the tumor microenvironment comprising at least one CAF, the conjugate having a structure
wherein L comprises a bivalent linker and X comprises a near infrared (NIR) dye;
causing the NIR dye to fluoresce through an application of an optical stimulus thereto; and
cutting CAF-containing tissue of the patient based on a result of the fluorescence.
37. The method of claim 36, wherein the CAF-containing tissue imaged by the conjugate comprises stromal cells.
38. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein A is a drug selected from the group consisting of a vinca alkaloid, a cryptophycin, bortezomib, thiobortezomib, a tubulysin, aminopterin, rapamycin, paclitaxel, docetaxel, doxorubicin, daunorubicin, everolimus, a-amanatin, verucarin, didemnin B, geldanomycin, purvalanol A, ispinesib, budesonide, dasatinib, an epothilone, a maytansine, and a tyrosine kinase inhibitor.
39. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the drug is a tubulysin.
40. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the drug is a tetrapeptide of the formula
wherein
Rla, R3a, R3a and R3a are each independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen
atom in Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently optionally substituted by halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, 5- to 7-membered heteroaryl, -OR13a, - OC(0)R13a, -OC(0)NR13aR13a', -OS(0)R13a, -OS(0)2R13a, -SR13a, -SC(0)R13a, -S(0)R13a, - S(0)2R13a, -S(0)2OR13a, -S(0)NR13aR13a', -S(0)2NR13aR13a', -OS(0)NR13aR13a',
-OS(0)2NR13aR13a', -NR13aR13a', -NR13aC(0)R14a, -NR13aC(0)OR14a, -NR13aC(0)NR14aR14a', -NR13aS(0)R14a, -NR13aS(0)2R14a, -NR13aS(0)NR13aR14a', -NR13aS(0)2NR14aR14a',
-P(0)(OR13a)2, -C(0)R13a, -C(0)OR13a or -C(0)NR13aR13a';
R2a, R4a and R12a are each independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl;
R5a and R6a are each independently selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR15a, -SR15a and -NR15aR15a', wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl and C2_C6 alkynyl is independently optionally substituted by halogen, -OR16a, -SR16a, -NR16aR16a', -C(0)R16a, -C(0)OR16a or -C(0)NR16aR16a ; or R5a and R6a taken together with the carbon atom to which they are attached form a -C(O)-;
each R7a, R8a, R9a, R10a and Rlla is independently selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -CN, -N02, -NCO, -OR17a, -SR17a, -S(0)2OR17a, -NR17aR17a', -P(0)(OR17a)2, -C(0)R17a, -C(0)OR17a and -C(0)NR17aR17a', wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl is independently optionally substituted by halogen, -OR18a, -SR18a, -NR18aR18a', -C(0)R18a, -C(0)OR18a or -C(0)NR18aR18a';
each R13a, R13a', R14a, R14a', R15a, R15a', R16a, R16a', R17a and R17a' is independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in Ci-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH, -NH2 or -C02H;
each R 18a and R 18a' is independently selected from the group consisting of H, C\- C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-Cio aryl, 5- to 7-membered heteroaryl -C(0)R19a, -P(0)(OR19a)2, and -S(0)2OR19a,
each R19a is independently selected from H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7- membered heteroaryl; and
a is 1, 2 or 3.
41. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein D is a tetrapeptide of the formula
wherein
Rla, R3a, R3a and R3a are each independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3-C6 cycloalkyl is independently optionally substituted by halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, 5- to 7-membered heteroaryl, -OR13a, - OC(0)R13a, -OC(0)NR13aR13a', -OS(0)R13a, -OS(0)2R13a, -SR13a, -SC(0)R13a, -S(0)R13a, - S(0)2R13a, -S(0)2OR13a, -S(0)NR13aR13a', -S(0)2NR13aR13a', -OS(0)NR13aR13a',
-OS(0)2NR13aR13a', -NR13aR13a', -NR13aC(0)R14a, -NR13aC(0)OR14a, -NR13aC(0)NR14aR14a', -NR13aS(0)R14a, -NR13aS(0)2R14a, -NR13aS(0)NR13aR14a', -NR13aS(0)2NR14aR14a',
-P(0)(OR13a)2, -C(0)R13a, -C(0)OR13a or -C(0)NR13aR13a';
R2a, R4a and R12a are each independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl;
R5a is selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR15a, -SR15a and -NR15aR15a', wherein each hydrogen atom in Ci-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl is independently optionally substituted by halogen, - OR16a, -SR16a, -NR16aR16a', -C(0)R16a, -C(0)OR16a or -C(0)NR16aR16a';
each R7a, R8a, R9a, R10a and Rlla is independently selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -CN, -N02, -NCO, -OR17a, -SR17a, -S(0)2OR17a, -NR17aR17a', -P(0)(OR17a)2, -C(0)R17a, -C(0)OR17a and -C(0)NR17aR17a', wherein each hydrogen atom in Q-C6 alkyl, C2-C6 alkenyl and C2_C6 alkynyl is independently optionally substituted by halogen, -OR18a, -SR18a, -NR18aR18a', -C(0)R18a, -C(0)OR18a or -C(0)NR18aR18a';
each R13a, R13a', R14a, R14a', R15a, R15a', R16a, R16a', R17a and R17a' is independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7-
membered heteroaryl, wherein each hydrogen atom in Q-G7 alkyl, C2-C7 alkenyl, C2-C7 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH, -N¾ or -CO2H;
each R 18a and R 18a' is independently selected from the group consisting of H, Ci- C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-Cio aryl, 5- to 7-membered heteroaryl -C(0)R19a, -P(0)(OR19a)2, and -S(0)2OR19a,
each R19a is independently selected from H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7- membered heteroaryl; and
a is 1, 2 or 3.
42. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein D is a tetra eptide of the formula
wherein
R9a is selected from the group consisting of H, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -CN, -N02, -NCO, -OR17a, -SR17a, -S(0)2OR17a, -NR17aR17a', - P(0)(OR17a)2, -C(0)R17a, -C(0)OR17a and -C(0)NR17aR17a', wherein each hydrogen atom in C C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl is independently optionally substituted by halogen, - OR18a, -SR18a, -NR18aR18a', -C(0)R18a, -C(0)OR18a or -C(0)NR18aR18a';
each R13a, R17a and R17a is independently selected from the group consisting of H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-Cio aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C7 alkyl, C2-C7 alkenyl, C2-C7 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-Cio aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by halogen, -OH, -SH, -NH2 or -C02H;
each R 18a and R 18a' is independently selected from the group consisting of H, C\- C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, 5- to 7-membered heteroaryl -C(0)R19a, -P(0)(OR19a)2, and -S(0)2OR19a, and
each R19a is independently selected from H, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl and 5- to 7- membered heteroaryl.
43. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein A is a naturally occurring tubulysin.
44. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of tubulysin A, tubulysin B, tubulysin C, tubulysin D, tubulysin E, tubulysin F, tubulysin G, tubulysin H and tubulysin I.
45. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the drug is tubulysin B.
46. The conjugate of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein A is of the formula
47. The conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is of the formula
48. A con ugate of the formula
49. The conjugate of claim 48, or a pharmaceutically acceptable salt thereof, wherein the conjugate comprises a radioactive metal isotope selected from the group consisting of mIn, 99mTc, ^Cu, 67Cu, 67Ga and 68Ga coordinated thereto.
50. The conjugate of claim 49, wherein the radioactive metal isotope is
99mTc.
or a pharmaceutically acceptable salt thereof.
52. A conjugate of the formula
53. A pharmaceutical composition comprising a conjugate of claim 1, or a pharmaceutically acceptable salt thereof, and optionally at least one pharmaceutically acceptable excipient.
54. A method of treating cancer in a subject, comprising,
a. administering to the subject an effective amount of a conjugate or composition according to any one of claims 1, 38 to 47 or 51; or a pharmaceutically acceptable salt thereof.
55. The method of claim 54, wherein the subject has a FAP expressing cancer.
56. The method of claim 55, wherein FAP expressing cancer is primary or metastatic.
57. The method of claim 56, wherein the cancer is selected from the group consisting of prostate, endometrial, skin, pancreatic, breast, kidney, ovarian and brain cancer.
58. A conjugate according to any one of claim 1, 38 to 47 or 51, or a
pharmaceutically acceptable salt thereof, for use in a method of treating FAP expressing cancer in a subject.
59. The conjugate of claim 58, wherein the method comprises administering to the subject an amount of the conjugate effective for treating the FAP expressing cancer.
60. The conjugate of claim 59, wherein the FAP expressing cancer is selected from the group consisting of prostate, endometrial, skin, pancreatic, breast, kidney, ovarian and brain cancer.
61. Use of a conjugate according to any one of claims 1, 38 to 47 or 51, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament useful for treating FAP expressing cancer in a subject.
62. The use of claim 61, wherein the FAP expressing cancer is selected from the group consisting of prostate, endometrial, skin, pancreatic, breast, kidney, ovarian and brain cancer.
63. A method of imaging a population of cells in vitro, comprising a. contacting the cells with a conjugate according to any one of claims 1 to 31, to provide labelled cells, and
b. visualizing the labelled cells.
64. A conjugate according to any one of claims 1 to 31, for use in a method of imaging a population of cells in vitro.
65. The conjugate of claim 64, wherein the method comprises
a. contacting the cells with a conjugate according to any one of claims 1 to 31, to provide labelled cells, and
b. visualizing the labelled cells.
66. A method of imaging a population of cells in vivo, comprising a. administering to a patient an effective amount of a conjugate according to any one of claims 1 to 23, 32, 33, 48 or 49, or a pharmaceutically acceptable salt thereof, to provide labelled cells; and
b. visualizing the labelled cells by imaging.
67. A conjugate according to any one of claims 1 to 23, 32, 33, 48 or 49, for use in a method of imaging a population of cells in vitro.
68. The conjugate of claim 67, wherein the method comprises
a. administering to a patient an effective amount of a conjugate according to any one of claims 1 to 23, 32, 33, 48 or 49, or a pharmaceutically acceptable salt thereof, to provide labelled cells; and
b. visualizing the labelled cells by imaging.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310269637.XA CN116474108A (en) | 2016-12-14 | 2017-12-13 | Fibroblast Activation Protein (FAP) -targeted imaging and therapy |
EP17880889.5A EP3555627B1 (en) | 2016-12-14 | 2017-12-13 | Fibroblast activation protein (fap)-targeted imaging and therapy |
ES17880889T ES2972577T3 (en) | 2016-12-14 | 2017-12-13 | Imaging and therapy targeting fibroblast activation protein (FAP) |
JP2019531797A JP7162592B2 (en) | 2016-12-14 | 2017-12-13 | Fibroblast activation protein (FAP) targeted imaging and therapy |
US16/469,907 US20200237936A1 (en) | 2016-12-14 | 2017-12-13 | Fibroblast activation protein (fap)-targeted imaging and therapy |
CN201780086490.3A CN110291401B (en) | 2016-12-14 | 2017-12-13 | Fibroblast Activation Protein (FAP) -targeted imaging and therapy |
US17/245,872 US11872291B2 (en) | 2016-12-14 | 2021-04-30 | Fibroblast activation protein (FAP)-targeted imaging and therapy |
US17/553,113 US20220105208A1 (en) | 2016-12-14 | 2021-12-16 | Fibroblast activation protein (fap)-targeted imaging and therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662434380P | 2016-12-14 | 2016-12-14 | |
US62/434,380 | 2016-12-14 | ||
US201762575050P | 2017-10-20 | 2017-10-20 | |
US62/575,050 | 2017-10-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/469,907 A-371-Of-International US20200237936A1 (en) | 2016-12-14 | 2017-12-13 | Fibroblast activation protein (fap)-targeted imaging and therapy |
US17/245,872 Continuation US11872291B2 (en) | 2016-12-14 | 2021-04-30 | Fibroblast activation protein (FAP)-targeted imaging and therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018111989A1 true WO2018111989A1 (en) | 2018-06-21 |
Family
ID=62559225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/065995 WO2018111989A1 (en) | 2016-12-14 | 2017-12-13 | Fibroblast activation protein (fap)-targeted imaging and therapy |
Country Status (6)
Country | Link |
---|---|
US (3) | US20200237936A1 (en) |
EP (1) | EP3555627B1 (en) |
JP (1) | JP7162592B2 (en) |
CN (2) | CN116474108A (en) |
ES (1) | ES2972577T3 (en) |
WO (1) | WO2018111989A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
WO2020081522A1 (en) * | 2018-10-17 | 2020-04-23 | Purdue Research Foundation | Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis |
WO2020132661A3 (en) * | 2018-12-21 | 2020-07-30 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
WO2021016392A1 (en) * | 2019-07-22 | 2021-01-28 | Purdue Research Foundation | Multivalent fibroblast-targeted agents and methods of use |
WO2021055641A1 (en) * | 2019-09-17 | 2021-03-25 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases |
WO2021155292A1 (en) * | 2020-01-31 | 2021-08-05 | Philip Stewart Low | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
WO2021160825A1 (en) | 2020-02-12 | 2021-08-19 | Philochem Ag | Fibroblast activation protein ligands for targeted delivery applications |
GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
WO2021195198A1 (en) * | 2020-03-24 | 2021-09-30 | Trustees Of Tufts College | Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto |
CN113521313A (en) * | 2021-07-22 | 2021-10-22 | 戴格普瑞生物科技(苏州)有限公司 | Targeted contrast agent, product, preparation method and application |
WO2021207682A3 (en) * | 2020-04-09 | 2021-11-04 | Philip Stewart Low | Pi3 kinase inhibitors and uses thereof |
WO2021224438A1 (en) | 2020-05-07 | 2021-11-11 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
EP3723753A4 (en) * | 2017-12-15 | 2022-01-26 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
EP3833400A4 (en) * | 2018-08-07 | 2022-06-15 | Purdue Research Foundation | Rejuvenation of car t cell |
WO2022133288A1 (en) * | 2020-12-17 | 2022-06-23 | Trustees Of Tufts College | Fap-activated radiotheranostics, and uses related thereto |
WO2022135325A1 (en) * | 2020-12-21 | 2022-06-30 | 苏州药明博锐生物科技有限公司 | Fibroblast activated protein inhibitor |
EP4043452A1 (en) | 2021-02-12 | 2022-08-17 | Philochem AG | Bivalent fibroblast activation protein ligands for targeted delivery applications |
WO2022171811A1 (en) | 2021-02-12 | 2022-08-18 | Philochem Ag | Bivalent fibroblast activation protein ligands for targeted delivery applications |
US20230112012A1 (en) * | 2018-02-06 | 2023-04-13 | Universität Heidelberg | Fap inhibitor |
WO2023057457A1 (en) | 2021-10-04 | 2023-04-13 | Philochem Ag | Radiolabelled fibroblast activation protein ligands |
WO2023144379A1 (en) | 2022-01-30 | 2023-08-03 | Philochem Ag | High-affinity ligands of fibroblast activation protein for targeted delivery applications |
RU2802426C2 (en) * | 2019-01-04 | 2023-08-28 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Fibroblast activation protein inhibitors |
US11872291B2 (en) | 2016-12-14 | 2024-01-16 | Purdue Research Foundation | Fibroblast activation protein (FAP)-targeted imaging and therapy |
WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202090776A1 (en) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | VISUALIZING AND RADIOTHERAPY AGENTS TARGETED ON FIBROBLAST-ACTIVATING PROTEIN ALPHA (FAPALPHA) |
JP2024510267A (en) * | 2021-03-16 | 2024-03-06 | パーデュー・リサーチ・ファウンデーション | Compounds that target fibroblast activation proteins and methods for their use |
CN117460826A (en) * | 2021-09-14 | 2024-01-26 | 菲柏生物医学技术(广州)有限公司 | siRNA conjugate targeting FAP positive cells, and pharmaceutical composition and application thereof |
CN114214061B (en) * | 2022-02-22 | 2022-05-17 | 北京大学 | Polyethylene glycol modified zwitterionic fluorescent probe, preparation and application thereof |
WO2024102956A1 (en) * | 2022-11-09 | 2024-05-16 | Purdue Research Foundation | Keto-amide-based fibroblast activation protein-targeted ligand linked to an imaging or therapeutic agent, compositions and methods of use |
CN116621823B (en) * | 2023-07-06 | 2023-10-31 | 南京诺源医疗器械有限公司 | Near infrared fluorescent tracer for diagnosing metastatic lymph nodes, synthetic method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138432A1 (en) * | 1999-11-15 | 2003-07-24 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs |
US20110117025A1 (en) * | 2008-05-20 | 2011-05-19 | Ralph Sebastian Dacosta | Device and method for fluorescence-based imaging and monitoring |
US20140099340A1 (en) * | 2012-10-01 | 2014-04-10 | The Wistar Institute Of Anatomy And Biology | Compositions and Methods for Targeting Stromal Cells for the Treatment of Cancer |
US20140271482A1 (en) * | 2013-03-15 | 2014-09-18 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767242A (en) | 1994-04-20 | 1998-06-16 | Boehringer Ingelheim Int'l Gmbh | Isolated dimeric fibroblast activation protein alpha, and uses thereof |
US5851775A (en) | 1997-03-20 | 1998-12-22 | Johns Hopkins University | β-catenin, Tcf-4, and APC interact to prevent cancer |
US20020004490A1 (en) | 1999-04-12 | 2002-01-10 | Dean Nicholas M. | Antisense modulation of Fas mediated signaling |
WO1999047152A2 (en) | 1998-03-20 | 1999-09-23 | Sloan Kettering Institute For Cancer Research | Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells |
EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
GB9827430D0 (en) | 1998-12-11 | 1999-02-03 | Ludwig Inst Cancer Res | Differential expression in primary breast cancer |
AU2001256325A1 (en) | 2000-03-17 | 2001-09-24 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
EP1784645A2 (en) | 2004-07-29 | 2007-05-16 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with fibroblast activation protein |
US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
EP1812458A2 (en) | 2004-10-27 | 2007-08-01 | Wen-Tien Chen | Methods and compositions for seprase inactivation |
WO2006125227A2 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
US7998997B2 (en) | 2005-07-05 | 2011-08-16 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
WO2007111657A2 (en) | 2005-12-14 | 2007-10-04 | Ludwig Institute For Cancer Research | Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein |
WO2007087131A2 (en) | 2006-01-05 | 2007-08-02 | The Johns Hopkins University | Peptide prodrugs |
MX2008015649A (en) | 2006-06-07 | 2009-03-25 | Patrick A Mckee | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use. |
ES2393372T3 (en) | 2006-06-21 | 2012-12-20 | The Scripps Research Institute | DNA composition against the FAP stromal tumor antigen and methods of use thereof |
ATE472602T1 (en) | 2006-07-25 | 2010-07-15 | Pasteur Institut | RECOMBINANT MYCOBACTERIA STRAIN EXPRESSING A FAP PROTEIN FROM MYCOBACTERIA UNDER THE CONTROL OF A PROMOTER ACTIVE UNDER HYPOXIC CONDITIONS AND THE USE THEREOF FOR TUMOR THERAPY |
WO2008028000A2 (en) | 2006-08-29 | 2008-03-06 | Molecular Insight Pharmaceuticals, Inc. | Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases |
WO2008116053A2 (en) | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Fap-activated chemotherapeutic compounds, and methods of use thereof |
JP2010523477A (en) | 2007-03-20 | 2010-07-15 | トラスティーズ オブ タフツ カレッジ | Inhibitors of fibroblast activation protein and methods of using the same |
JP5769966B2 (en) | 2007-08-17 | 2015-08-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Purine derivatives for the treatment of FAB-related diseases |
PL2187965T3 (en) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
PL2223115T3 (en) | 2007-12-10 | 2012-02-29 | Hoffmann La Roche | Seprase as a marker for cancer |
WO2009139915A2 (en) | 2008-05-15 | 2009-11-19 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
WO2010036814A1 (en) | 2008-09-25 | 2010-04-01 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
EP2389176A4 (en) | 2009-01-23 | 2012-08-01 | Univ Sydney | Novel metabolic disease therapy |
US10815517B2 (en) | 2009-04-28 | 2020-10-27 | Roche Diagnostics Operations, Inc. | Use of DPPIV/seprase as a marker for cancer |
WO2011040973A2 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
WO2011040972A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
EP2397466B1 (en) | 2010-06-15 | 2012-11-28 | Centre National De La Recherche Scientifique CNRS | X-ray and gamma-photon activatable organic compounds, their preparation and their uses |
JP2013540991A (en) | 2010-08-27 | 2013-11-07 | ユニバーシティ・オブ・チューリッヒ | Novel diagnostic and therapeutic targets in inflammation and / or cardiovascular disease |
CN103945856A (en) | 2011-08-30 | 2014-07-23 | 塔夫茨大学信托人 | FAP-activated proteasome inhibitors for treating solid tumors |
WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
WO2013166438A1 (en) | 2012-05-04 | 2013-11-07 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of prolyl oligopeptidase and fibroblast activation protein and methods of use |
US20150320892A1 (en) | 2012-06-29 | 2015-11-12 | Ge Healthcare Limited | Imaging fibrosis |
US20150202218A1 (en) | 2012-08-02 | 2015-07-23 | Trustees Of Tufts College | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections |
JP6404824B2 (en) | 2012-11-09 | 2018-10-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | In vitro capture and analysis of circulating tumor cells |
US9402888B2 (en) | 2013-03-14 | 2016-08-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
UA118028C2 (en) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
WO2014167083A1 (en) | 2013-04-12 | 2014-10-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
CA2911414C (en) | 2013-05-13 | 2018-09-11 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
CN103267852B (en) | 2013-05-15 | 2015-03-25 | 中国医学科学院北京协和医院 | Application of fibroblast activation protein (FAP) alpha to preparation of pancreatic cancer prognosis kit |
GB2538023A (en) | 2014-02-03 | 2016-11-02 | Philochem Ag | Targeted drug conjugates |
WO2015192123A1 (en) | 2014-06-13 | 2015-12-17 | Trustees Of Tufts College | Fap-activated therapeutic agents, and uses related thereto |
US9737556B2 (en) | 2014-06-13 | 2017-08-22 | Trustees Of Tufts College | FAP-activated therapeutic agents, and uses related thereto |
RU2017116020A (en) | 2014-10-08 | 2018-11-12 | Ф.Хоффманн-Ля Рош Аг | COMBINED THERAPY BY SPECIFIC ANTIBODIES SPECIFIC TO FAP AND DR5, AND CHEMOTHERAPEUTIC AGENTS |
WO2016089879A1 (en) * | 2014-12-01 | 2016-06-09 | Endocyte, Inc. | Conjugates of garftase inhibitors |
US20170369592A1 (en) | 2015-01-09 | 2017-12-28 | Mabimmune Diagostics AG | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof |
WO2016146174A1 (en) | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
WO2016164815A1 (en) | 2015-04-10 | 2016-10-13 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
US20160303251A1 (en) * | 2015-04-17 | 2016-10-20 | Endocyte, Inc. | Conjugates of garftase inhibitors |
HRP20240215T1 (en) | 2016-03-22 | 2024-04-26 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
WO2017189569A1 (en) | 2016-04-25 | 2017-11-02 | Trustees Of Tufts College | Multimediator dpp4 and fap inhibitors, and uses related thereto |
CN106046121B (en) | 2016-06-20 | 2020-06-16 | 郑州大学 | FAP-targeted anti-angiogenesis peptide Z-GP-V1 and application thereof |
CN105949282B (en) | 2016-06-20 | 2020-06-16 | 郑州大学 | FAP-targeted anti-angiogenesis peptide Z-GP-V2 and application thereof |
JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
CN116474108A (en) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | Fibroblast Activation Protein (FAP) -targeted imaging and therapy |
WO2018187418A1 (en) | 2017-04-04 | 2018-10-11 | Genentech, Inc. | Substrates recognized by fibroblast activation protein (fap) and methods of using the same |
EA202090776A1 (en) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | VISUALIZING AND RADIOTHERAPY AGENTS TARGETED ON FIBROBLAST-ACTIVATING PROTEIN ALPHA (FAPALPHA) |
CN109796532A (en) | 2017-11-17 | 2019-05-24 | 科济生物医药(上海)有限公司 | Target combining unit and its application of fibroblast activation protein α |
CN108152258A (en) | 2017-12-13 | 2018-06-12 | 清华大学 | A kind of method for detecting the content of aminoglycoside antibiotics in solution to be measured |
AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
CN108333365B (en) | 2018-01-24 | 2020-09-04 | 南开大学 | In-situ excitation-free detection of fibroblast activation protein by using gold-long afterglow nanoparticles |
WO2019154859A1 (en) | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
CN112912731A (en) | 2018-10-17 | 2021-06-04 | 普渡研究基金会 | Fibroblast Activation Protein (FAP) targeted imaging and fibrosis therapy |
GB201820320D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for FAPalpha |
EP3906024A4 (en) | 2019-01-04 | 2022-10-26 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
CN110368496B (en) | 2019-07-11 | 2020-12-29 | 同济大学 | Use of fibroblast activation protein inhibitor in preparation of medicine |
CN111574634B (en) | 2019-12-16 | 2022-04-19 | 四川大学华西医院 | Double-target chimeric antigen receptor simultaneously targeting mesothelin and FAP and application thereof |
CN111235221B (en) | 2020-01-22 | 2022-08-05 | 北京大学第一医院 | Method for detecting activity of FAP inhibitor |
-
2017
- 2017-12-13 CN CN202310269637.XA patent/CN116474108A/en active Pending
- 2017-12-13 JP JP2019531797A patent/JP7162592B2/en active Active
- 2017-12-13 CN CN201780086490.3A patent/CN110291401B/en active Active
- 2017-12-13 US US16/469,907 patent/US20200237936A1/en not_active Abandoned
- 2017-12-13 ES ES17880889T patent/ES2972577T3/en active Active
- 2017-12-13 WO PCT/US2017/065995 patent/WO2018111989A1/en unknown
- 2017-12-13 EP EP17880889.5A patent/EP3555627B1/en active Active
-
2021
- 2021-04-30 US US17/245,872 patent/US11872291B2/en active Active
- 2021-12-16 US US17/553,113 patent/US20220105208A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138432A1 (en) * | 1999-11-15 | 2003-07-24 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs |
US20110117025A1 (en) * | 2008-05-20 | 2011-05-19 | Ralph Sebastian Dacosta | Device and method for fluorescence-based imaging and monitoring |
US20140099340A1 (en) * | 2012-10-01 | 2014-04-10 | The Wistar Institute Of Anatomy And Biology | Compositions and Methods for Targeting Stromal Cells for the Treatment of Cancer |
US20140271482A1 (en) * | 2013-03-15 | 2014-09-18 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Non-Patent Citations (3)
Title |
---|
"Remington: The Science & Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS |
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY |
FISCHER ET AL.: "investigate a radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies", CLIN. CANCER RES, vol. 18, no. 22, pages 6208 - 6218, XP055257958, DOI: 10.1158/1078-0432.CCR-12-0644 |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11872291B2 (en) | 2016-12-14 | 2024-01-16 | Purdue Research Foundation | Fibroblast activation protein (FAP)-targeted imaging and therapy |
US11780821B2 (en) | 2017-12-15 | 2023-10-10 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
EP3723753A4 (en) * | 2017-12-15 | 2022-01-26 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
US20230112012A1 (en) * | 2018-02-06 | 2023-04-13 | Universität Heidelberg | Fap inhibitor |
EP3833400A4 (en) * | 2018-08-07 | 2022-06-15 | Purdue Research Foundation | Rejuvenation of car t cell |
US11426472B2 (en) | 2018-10-17 | 2022-08-30 | Purdue Research Foundation | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis |
EP3867648A4 (en) * | 2018-10-17 | 2022-06-22 | Purdue Research Foundation | Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis |
US11890357B2 (en) | 2018-10-17 | 2024-02-06 | Purdue Research Foundation | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis |
WO2020081522A1 (en) * | 2018-10-17 | 2020-04-23 | Purdue Research Foundation | Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis |
US11504364B2 (en) | 2018-12-21 | 2022-11-22 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
WO2020132661A3 (en) * | 2018-12-21 | 2020-07-30 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
CN113811529A (en) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | Fibroblast activation protein inhibitor |
RU2802426C2 (en) * | 2019-01-04 | 2023-08-28 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Fibroblast activation protein inhibitors |
EP4003321A4 (en) * | 2019-07-22 | 2024-01-03 | Purdue Research Foundation | Multivalent fibroblast-targeted agents and methods of use |
CN114340610A (en) * | 2019-07-22 | 2022-04-12 | 普渡研究基金会 | Multivalent fibroblast targeting agents and methods of use |
WO2021016392A1 (en) * | 2019-07-22 | 2021-01-28 | Purdue Research Foundation | Multivalent fibroblast-targeted agents and methods of use |
CN114901315A (en) * | 2019-09-17 | 2022-08-12 | 普渡研究基金会 | Fibroblast Activation Protein (FAP) -targeted imaging and treatment of cancer and other fibrotic and inflammatory diseases |
WO2021055641A1 (en) * | 2019-09-17 | 2021-03-25 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases |
EP4096677A4 (en) * | 2020-01-31 | 2024-02-28 | Purdue Research Foundation | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
EP4096676A4 (en) * | 2020-01-31 | 2024-04-10 | Purdue Research Foundation | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
WO2021155288A1 (en) * | 2020-01-31 | 2021-08-05 | Philip Stewart Low | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
WO2021155292A1 (en) * | 2020-01-31 | 2021-08-05 | Philip Stewart Low | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
WO2021160825A1 (en) | 2020-02-12 | 2021-08-19 | Philochem Ag | Fibroblast activation protein ligands for targeted delivery applications |
EP4019507A1 (en) | 2020-02-12 | 2022-06-29 | Philochem AG | Fibroblast activation protein ligands for targeted delivery applications |
WO2021195198A1 (en) * | 2020-03-24 | 2021-09-30 | Trustees Of Tufts College | Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto |
US11707539B2 (en) | 2020-03-24 | 2023-07-25 | Trustees Of Tufts College | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto |
WO2021207682A3 (en) * | 2020-04-09 | 2021-11-04 | Philip Stewart Low | Pi3 kinase inhibitors and uses thereof |
WO2021224438A1 (en) | 2020-05-07 | 2021-11-11 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
WO2022133288A1 (en) * | 2020-12-17 | 2022-06-23 | Trustees Of Tufts College | Fap-activated radiotheranostics, and uses related thereto |
WO2022135325A1 (en) * | 2020-12-21 | 2022-06-30 | 苏州药明博锐生物科技有限公司 | Fibroblast activated protein inhibitor |
WO2022171811A1 (en) | 2021-02-12 | 2022-08-18 | Philochem Ag | Bivalent fibroblast activation protein ligands for targeted delivery applications |
EP4043452A1 (en) | 2021-02-12 | 2022-08-17 | Philochem AG | Bivalent fibroblast activation protein ligands for targeted delivery applications |
WO2023283627A1 (en) | 2021-07-09 | 2023-01-12 | Blue Earth Diagnostics Limited | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
CN113521313A (en) * | 2021-07-22 | 2021-10-22 | 戴格普瑞生物科技(苏州)有限公司 | Targeted contrast agent, product, preparation method and application |
WO2023057457A1 (en) | 2021-10-04 | 2023-04-13 | Philochem Ag | Radiolabelled fibroblast activation protein ligands |
WO2023144379A1 (en) | 2022-01-30 | 2023-08-03 | Philochem Ag | High-affinity ligands of fibroblast activation protein for targeted delivery applications |
WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
Also Published As
Publication number | Publication date |
---|---|
JP2020502130A (en) | 2020-01-23 |
CN116474108A (en) | 2023-07-25 |
CN110291401A (en) | 2019-09-27 |
US20220105208A1 (en) | 2022-04-07 |
US20200237936A1 (en) | 2020-07-30 |
US11872291B2 (en) | 2024-01-16 |
EP3555627A4 (en) | 2020-08-19 |
ES2972577T3 (en) | 2024-06-13 |
EP3555627B1 (en) | 2023-11-22 |
CN110291401B (en) | 2023-04-11 |
JP7162592B2 (en) | 2022-10-28 |
EP3555627A1 (en) | 2019-10-23 |
US20210316018A1 (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11872291B2 (en) | Fibroblast activation protein (FAP)-targeted imaging and therapy | |
US11883498B2 (en) | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | |
EP2822386B1 (en) | Folate receptor alpha binding ligands | |
AU2020201329A1 (en) | Conjugates for treating diseases caused by PSMA expressing cells | |
US11524082B2 (en) | FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers | |
US10857234B2 (en) | Carbonic anhydrase IX inhibitor conjugates and uses thereof | |
US11925696B2 (en) | Carbonic anhydrase IX targeting agents and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17880889 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019531797 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017880889 Country of ref document: EP Effective date: 20190715 |